1
|
Weirauch T, Burger G, Cadar D, Gabriel M, Koepsell J, Schüttfort G, de Leuw P, Bickel M, Vehreschild MJGT, Wolf T, Wetzstein N. Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir. Int J Infect Dis 2024; 143:107017. [PMID: 38521450 DOI: 10.1016/j.ijid.2024.107017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 03/19/2024] [Accepted: 03/19/2024] [Indexed: 03/25/2024] Open
Abstract
Yellow fever (YF) is a potentially lethal viral hemorrhagic fever that can be prevented with the 17D live attenuated YF vaccine. However, this vaccination can cause severe adverse reactions including vaccine-associated YF. Here, we describe the case of a 32-year-old female who was permanently immunosuppressed with an anti-CD20 antibody due to multiple sclerosis. Following YF vaccination, the patient developed a variety of symptoms such as febrile temperatures, muscle and joint pain, headaches, and dysuria. A vaccine-associated YF with viremia was diagnosed. To avoid a potentially severe course of the disease, sofosbuvir was used as antiviral treatment followed by the resolution of symptoms and serological response. As travelers with chronic diseases and immunosuppression will increasingly engage in long distance travel, this case demonstrates the importance of assessing patient history prior to the administration of live vaccines and points towards a possible therapeutic approach in those suffering from vaccine-associated YF.
Collapse
Affiliation(s)
- Tobias Weirauch
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
| | - Gerrit Burger
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Dániel Cadar
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Martin Gabriel
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Julia Koepsell
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Gundolf Schüttfort
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | | | | | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Nils Wetzstein
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| |
Collapse
|
2
|
Kessel J, Rosanas-Urgell A, Dingwerth T, Goetsch U, Haller J, Huits R, Kattenberg JH, Meinecke A, Monsieurs P, Sroka M, Witte T, Wolf T. Investigation of an airport-associated cluster of falciparum malaria in Frankfurt, Germany, 2022. Euro Surveill 2024; 29:2300298. [PMID: 38304950 PMCID: PMC10835754 DOI: 10.2807/1560-7917.es.2024.29.5.2300298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Accepted: 09/19/2023] [Indexed: 02/03/2024] Open
Abstract
Airport malaria is uncommon but increasing in Europe and often difficult to diagnose. We describe the clinical, epidemiological and environmental investigations of a cluster of airport malaria cases and measures taken in response. Three Frankfurt International Airport employees without travel histories to malaria-endemic areas were diagnosed with Plasmodium falciparum malaria in Germany in 2022. Two cases were diagnosed within 1 week, and the third one after 10 weeks. Two cases had severe disease, all three recovered fully. The cases worked in separate areas and no specific location for the transmissions could be identified. No additional cases were detected among airport employees. In June and July, direct flights from Equatorial Guinea, Nigeria and Angola and one parcel originating in Ghana arrived at Frankfurt airport. No vector-competent mosquitoes could be trapped to identify the source of the outbreak. Whole genome sequencing of P. falciparum genomes showed a high genetic relatedness between samples of the three cases and suggested the geographical origin closest to Ghana. A diagnosis of airport malaria should prompt appropriate and comprehensive outbreak investigations to identify the source and to prevent severe forms of falciparum malaria.
Collapse
Affiliation(s)
- Johanna Kessel
- Goethe University, University Hospital Frankfurt, Department of Infectious Diseases, Frankfurt, Germany
| | - Anna Rosanas-Urgell
- Unit of Malariology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - Tobias Dingwerth
- Medical Center Frankfurt, Medical Services & Health Management Lufthansa Group, Frankfurt, Germany
| | - Udo Goetsch
- Municipal Health Protection Authority, Frankfurt, Germany
| | - Jonas Haller
- Goethe University, Department of Integrative parasitology and animal physiology, Frankfurt, Germany
- Municipal Health Protection Authority, Frankfurt, Germany
| | - Ralph Huits
- Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy
| | - Johanna H Kattenberg
- Unit of Malariology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - Anna Meinecke
- Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany
| | - Pieter Monsieurs
- Unit of Malariology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | | | - Torsten Witte
- Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany
| | - Timo Wolf
- Goethe University, University Hospital Frankfurt, Department of Infectious Diseases, Frankfurt, Germany
| |
Collapse
|
3
|
Harrer CE, Mayer L, Fathi A, Lassen S, Ly ML, Zinser ME, Wolf T, Becker S, Sutter G, Dahlke C, Addo MM. Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans. J Infect Dis 2024:jiad612. [PMID: 38195212 DOI: 10.1093/infdis/jiad612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 12/19/2023] [Accepted: 12/29/2023] [Indexed: 01/11/2024] Open
Abstract
Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The Modified Vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of three candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A*03:01/HLA-B*35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.
Collapse
Affiliation(s)
- Caroline E Harrer
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Leonie Mayer
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Anahita Fathi
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
- First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Susan Lassen
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - My L Ly
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Madeleine E Zinser
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Timo Wolf
- Goethe University Frankfurt, University Hospital, Department of Internal Medicine II, Division of Infectious Diseases, Frankfurt am Main, Germany
| | - Stephan Becker
- German Center for Infection Research, partner site Gießen-Marburg-Langen, Germany
- Institute of Virology, Philipps University Marburg, Marburg, Germany
| | - Gerd Sutter
- German Center for Infection Research, partner site Munich, Germany
- Division of Virology, Institute for Infectious Diseases and Zoonoses, LMU Munich, Munich, Germany
| | - Christine Dahlke
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Marylyn M Addo
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
- German Center for Infection Research, partner sites Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
- First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
4
|
Schommers P, Kim DS, Schlotz M, Kreer C, Eggeling R, Hake A, Stecher M, Park J, Radford CE, Dingens AS, Ercanoglu MS, Gruell H, Odidika S, Dahlhaus M, Gieselmann L, Ahmadov E, Lawong RY, Heger E, Knops E, Wyen C, Kümmerle T, Römer K, Scholten S, Wolf T, Stephan C, Suárez I, Raju N, Adhikari A, Esser S, Streeck H, Duerr R, Nanfack AJ, Zolla-Pazner S, Geldmacher C, Geisenberger O, Kroidl A, William W, Maganga L, Ntinginya NE, Georgiev IS, Vehreschild JJ, Hoelscher M, Fätkenheuer G, Lavinder JJ, Bloom JD, Seaman MS, Lehmann C, Pfeifer N, Georgiou G, Klein F. Dynamics and durability of HIV-1 neutralization are determined by viral replication. Nat Med 2023; 29:2763-2774. [PMID: 37957379 PMCID: PMC10667105 DOI: 10.1038/s41591-023-02582-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Accepted: 09/07/2023] [Indexed: 11/15/2023]
Abstract
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl-1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response.
Collapse
Affiliation(s)
- Philipp Schommers
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Dae Sung Kim
- Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA
| | - Maike Schlotz
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Christoph Kreer
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Ralf Eggeling
- Methods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany
- Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany
| | - Anna Hake
- Research Group Computational Biology, Max Planck Institute for Informatics, Saarbrücken, Germany
- Saarland Informatics Campus, Saarbrücken, Germany
| | - Melanie Stecher
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Juyeon Park
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
| | - Caelan E Radford
- Molecular and Cellular Biology Graduate Program, University of Washington, and Basic Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA
- Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Adam S Dingens
- Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Meryem S Ercanoglu
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Henning Gruell
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Stanley Odidika
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - Marten Dahlhaus
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
| | - Lutz Gieselmann
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Elvin Ahmadov
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Rene Y Lawong
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Eva Heger
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Elena Knops
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Christoph Wyen
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Praxis am Ebertplatz, Cologne, Germany
| | | | - Katja Römer
- Gemeinschaftspraxis Gotenring, Cologne, Germany
| | | | - Timo Wolf
- Infectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany
| | - Christoph Stephan
- Infectious Diseases Division, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany
| | - Isabelle Suárez
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Nagarajan Raju
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Anurag Adhikari
- Department of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal
| | - Stefan Esser
- Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Hendrik Streeck
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
- Institute of Virology, Medical Faculty, University Bonn, Bonn, Germany
| | - Ralf Duerr
- Department of Microbiology, New York University School of Medicine, New York City, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, New York City, NY, USA
- Vaccine Center, NYU Grossman School of Medicine, New York City, NY, USA
| | - Aubin J Nanfack
- Medical Diagnostic Center, Yaoundé, Cameroon
- Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Susan Zolla-Pazner
- Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
- Department of Microbiology, Icahn School of Medicine, New York City, NY, USA
| | - Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany
| | - Otto Geisenberger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Arne Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Wiston William
- Mbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania
| | - Lucas Maganga
- Mbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania
| | | | - Ivelin S Georgiev
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA
- Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Computer Science, Vanderbilt University, Nashville, TN, USA
- Center for Structural Biology, Vanderbilt University, Nashville, TN, USA
| | - Jörg J Vehreschild
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany
- Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Gerd Fätkenheuer
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Jason J Lavinder
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
- Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA
| | - Jesse D Bloom
- Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA
- Howard Hughes Medical Institute, Seattle, WA, USA
| | - Michael S Seaman
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Clara Lehmann
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
| | - Nico Pfeifer
- Methods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany
- Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany
| | - George Georgiou
- Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
- Department of Chemical Engineering, University of Texas at Austin, Austin, TX, USA
| | - Florian Klein
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
- German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
| |
Collapse
|
5
|
Schmiedel S, Wolf T. [Ebola and Marburg virus disease]. Dtsch Med Wochenschr 2023; 148:1437-1442. [PMID: 37918428 DOI: 10.1055/a-1966-9615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2023]
Abstract
Viral hemorrhagic fevers (VHF) are serious, often fatal diseases that affect humans and non-human primates. The nomenclature of these diseases has changed in that they are now referred to as viral diseases because the previously named symptoms of fever or hemorrhages are not obligatory. In this article, the focus will be on the VHFs Ebola and Marburg viral disease with the potential for human-to-human transmission; these diseases are so-called high-consequence infectious diseases (HCID), some with considerable potential for epidemic spread and the risk of nosocomial transmission.
Collapse
Affiliation(s)
- Stefan Schmiedel
- Sektion Infektiologie, I. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf (UKE), Hamburg, Hamburg
| | - Timo Wolf
- Infektiologie, Zentrum für Innere Medizin 2, Klinikum der Johann-Wolfgang Goethe-Universität Frankfurt, Frankfurt
| |
Collapse
|
6
|
Hermanussen L, Brehm TT, Wolf T, Boesecke C, Schlabe S, Borgans F, Monin MB, Jensen BEO, Windhaber S, Scholten S, Jordan S, Lütgehetmann M, Wiesch JSZ, Addo MM, Mikolajewska A, Niebank M, Schmiedel S. Tecovirimat for the treatment of severe Mpox in Germany. Infection 2023; 51:1563-1568. [PMID: 37273167 PMCID: PMC10240449 DOI: 10.1007/s15010-023-02049-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 05/07/2023] [Indexed: 06/06/2023]
Abstract
BACKGROUND In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. METHODS We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. RESULTS A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. CONCLUSIONS In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.
Collapse
Affiliation(s)
- Lennart Hermanussen
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Thomas Theo Brehm
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
- German Center for Infection Research (DZIF), Partner-Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Timo Wolf
- Internal Medicine II, Department of Infectious Diseases, University Hospital, Frankfurt, Germany
| | - Christoph Boesecke
- Department of Medicine I, Bonn University Hospital, Bonn, Germany
- German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Bonn, Germany
| | - Stefan Schlabe
- Department of Medicine I, Bonn University Hospital, Bonn, Germany
| | - Frauke Borgans
- Internal Medicine II, Department of Infectious Diseases, University Hospital, Frankfurt, Germany
| | - Malte B Monin
- Department of Medicine I, Bonn University Hospital, Bonn, Germany
| | - Björn-Erik Ole Jensen
- Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf, Germany
| | - Stefan Windhaber
- Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf, Germany
| | - Stefan Scholten
- Praxis Hohenstaufenring in den RingColonnaden, Cologne, Germany
| | - Sabine Jordan
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Marc Lütgehetmann
- Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Julian Schulze Zur Wiesch
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
- German Center for Infection Research (DZIF), Partner-Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Marylyn M Addo
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
- German Center for Infection Research (DZIF), Partner-Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
- Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Agata Mikolajewska
- Centre for Biological Threats and Special Pathogens (ZBS), Robert Koch Institute, Berlin, Germany
| | - Michaela Niebank
- Centre for Biological Threats and Special Pathogens (ZBS), Robert Koch Institute, Berlin, Germany
| | - Stefan Schmiedel
- Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
| |
Collapse
|
7
|
Kessel J, Göymen E, Wolf T, Wetzstein N, Küpper-Tetzel C, Behrens P, Borgans F, Balaban Ü, Hogardt M, Wichelhaus TA, Stephan C. Time discrepancy for tuberculosis-negative microscopy and culture - the diagnostic gap remains: systematic analysis from a large tertiary care tuberculosis-clinic, Germany 2013-2017. Int J Infect Dis 2023; 134:269-272. [PMID: 37454889 DOI: 10.1016/j.ijid.2023.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 05/29/2023] [Accepted: 07/11/2023] [Indexed: 07/18/2023] Open
Abstract
OBJECTIVES Patients with open pulmonary tuberculosis (opTB) are subject to strict isolation rules. Sputum smear microscopy is used to determine infectivity, but sensitivity is lower than for culture. This study aimed to investigate the clinical relevance of this mismatch in contemporary settings. METHODS Differential results between microscopy and culture were determined at the time of microscopic sputum conversion, from all patients with opTB between 01/2013 and 12/2017. In addition, data on HIV, multi/extensive drug-resistant TB status, time to smear- and cultural-negativity conversion were analyzed; and a Kaplan-Meier curve was developed. RESULTS Of 118 patients with opTB, 58 had demographic data available for microbiological and clinical follow-up analysis; among these, 26 (44.8%) had still at least one positive culture result. Median time from opTB-treatment initiation to full microscopic sputum- or culture conversion, was 16.5 days (range 2-105), and 20 days (1-105), respectively (median difference: +3.5 days). Sixteen days after de-isolation, >90% had converted culturally. HIV- or multi/extensive drug-resistant TB status did not impact conversion time. CONCLUSION When patients with opTB were de-isolated after 3 negative sputum smear microscopy tests, a substantial part still revealed cultural growth of Mycobacterium tuberculosis complex, but it remains unclear, whether smear-negative and culturally-positive individuals on therapy are really infective. Thus, the clinical relevance of this finding warrants further investigation.
Collapse
Affiliation(s)
- Johanna Kessel
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Elif Göymen
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Nils Wetzstein
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Claus Küpper-Tetzel
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Pia Behrens
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Frauke Borgans
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Ümniye Balaban
- Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany
| | - Michael Hogardt
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Thomas A Wichelhaus
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Christoph Stephan
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
| |
Collapse
|
8
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. First Dark Matter Search with Nuclear Recoils from the XENONnT Experiment. Phys Rev Lett 2023; 131:041003. [PMID: 37566859 DOI: 10.1103/physrevlett.131.041003] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/22/2023] [Indexed: 08/13/2023]
Abstract
We report on the first search for nuclear recoils from dark matter in the form of weakly interacting massive particles (WIMPs) with the XENONnT experiment, which is based on a two-phase time projection chamber with a sensitive liquid xenon mass of 5.9 ton. During the (1.09±0.03) ton yr exposure used for this search, the intrinsic ^{85}Kr and ^{222}Rn concentrations in the liquid target are reduced to unprecedentedly low levels, giving an electronic recoil background rate of (15.8±1.3) events/ton yr keV in the region of interest. A blind analysis of nuclear recoil events with energies between 3.3 and 60.5 keV finds no significant excess. This leads to a minimum upper limit on the spin-independent WIMP-nucleon cross section of 2.58×10^{-47} cm^{2} for a WIMP mass of 28 GeV/c^{2} at 90% confidence level. Limits for spin-dependent interactions are also provided. Both the limit and the sensitivity for the full range of WIMP masses analyzed here improve on previous results obtained with the XENON1T experiment for the same exposure.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Bazyk
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E J Brookes
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | | | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Flierman
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - C Fuselli
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Guan
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N F Hood
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Lombardi
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - R Singh
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V H S Wu
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - Y Xing
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- INFN-Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, 44122 Ferrara, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
9
|
Aprile E, Abe K, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bazyk M, Bellagamba L, Biondi R, Bismark A, Brookes EJ, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Cardoso JMR, Cichon D, Cimental Chavez AP, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Flierman M, Fulgione W, Fuselli C, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Guan H, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Hood NF, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Pellegrini Q, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Pollmann TR, Qi J, Qin J, Ramírez García D, Singh R, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Wu VHS, Xing Y, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Searching for Heavy Dark Matter near the Planck Mass with XENON1T. Phys Rev Lett 2023; 130:261002. [PMID: 37450817 DOI: 10.1103/physrevlett.130.261002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/07/2023] [Accepted: 06/07/2023] [Indexed: 07/18/2023]
Abstract
Multiple viable theoretical models predict heavy dark matter particles with a mass close to the Planck mass, a range relatively unexplored by current experimental measurements. We use 219.4 days of data collected with the XENON1T experiment to conduct a blind search for signals from multiply interacting massive particles (MIMPs). Their unique track signature allows a targeted analysis with only 0.05 expected background events from muons. Following unblinding, we observe no signal candidate events. This Letter places strong constraints on spin-independent interactions of dark matter particles with a mass between 1×10^{12} and 2×10^{17} GeV/c^{2}. In addition, we present the first exclusion limits on spin-dependent MIMP-neutron and MIMP-proton cross sections for dark matter particles with masses close to the Planck scale.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Bazyk
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E J Brookes
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | | | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | | | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Flierman
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - C Fuselli
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Guan
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N F Hood
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Lombardi
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Q Pellegrini
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - T R Pollmann
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - R Singh
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik and Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - V H S Wu
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - Y Xing
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- INFN-Ferrara and Dipartimento di Fisica e Scienze della Terra, Università di Ferrara, 44122 Ferrara, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
10
|
Bojkova D, Bechtel M, Rothenburger T, Steinhorst K, Zöller N, Kippenberger S, Schneider J, Corman VM, Uri H, Wass MN, Knecht G, Khaykin P, Wolf T, Ciesek S, Rabenau HF, Michaelis M, Cinatl J. Drug Sensitivity of Currently Circulating Mpox Viruses. N Engl J Med 2023; 388:279-281. [PMID: 36577096 DOI: 10.1056/nejmc2212136] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Hannah Uri
- University of Kent, Canterbury, United Kingdom
| | - Mark N Wass
- University of Kent, Canterbury, United Kingdom
| | | | | | - Timo Wolf
- University Hospital, Frankfurt am Main, Germany
| | | | | | | | | |
Collapse
|
11
|
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer 2023; 4:96-107. [PMID: 36581734 PMCID: PMC9886549 DOI: 10.1038/s43018-022-00503-w] [Citation(s) in RCA: 16] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 11/29/2022] [Indexed: 04/26/2023]
Abstract
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response.
Collapse
Affiliation(s)
- Claudia M Denkinger
- Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
- Partner site Heidelberg University Hospital, German Center for Infection Research, Heidelberg, Germany.
| | - Maike Janssen
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Ulrike Schäkel
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Julia Gall
- NCT Trial Center, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - Albrecht Leo
- Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany
| | - Patrick Stelmach
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Stefan F Weber
- Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Johannes Krisam
- Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
| | - Lukas Baumann
- Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
| | - Jacek Stermann
- Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
| | - Uta Merle
- Department of Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany
| | - Markus A Weigand
- Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
| | - Christian Nusshag
- Department of Nephrology, University of Heidelberg, Heidelberg, Germany
| | - Lars Bullinger
- Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Jens-Florian Schrezenmeier
- Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Martin Bornhäuser
- Department of Internal Medicine I, University Hospital Dresden and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany
| | - Nael Alakel
- Department of Internal Medicine I, University Hospital Dresden and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany
| | - Oliver Witzke
- Department of Infectious Diseases, West German Centre for Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
| | - Stefan Schmiedel
- Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marylyn M Addo
- Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Partner site Hamburg-Lübeck-Borstel-Riems, German Center for Infection Research, Hamburg, Germany
- University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development, Hamburg, Germany
| | - Felix Herth
- Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany
| | - Michael Kreuter
- Center for Interstitial and Rare Lung Diseases, Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany
| | - Phil-Robin Tepasse
- Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany
| | | | - Mathias Hänel
- Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
| | - Anke Morgner
- Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
| | - Michael Kiehl
- Department of Internal Medicine I, Frankfurt (Oder) General Hospital, Frankfurt (Oder), Germany
| | - Olaf Hopfer
- Department of Internal Medicine I, Frankfurt (Oder) General Hospital, Frankfurt (Oder), Germany
| | - Mohammad-Amen Wattad
- Department of Hematology, Oncology, Palliative Care and Stem Cell Transplantation, Klinikum Hochsauerland, Meschede, Germany
| | - Carl C Schimanski
- Department of Internal Medicine II, Klinikum Darmstadt, Darmstadt, Germany
| | - Cihan Celik
- Department of Internal Medicine II, Klinikum Darmstadt, Darmstadt, Germany
| | - Thorsten Pohle
- Department of Internal Medicine I, Klinikum Herford, Herford, Germany
| | - Matthias Ruhe
- Department of Internal Medicine I, Klinikum Herford, Herford, Germany
| | - Winfried V Kern
- Department of Medicine II, Division of Infectious Diseases and Travel Medicine, University Medical Centre Freiburg, Freiburg, Germany
| | - Anita Schmitt
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Hanns-Martin Lorenz
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | | | - Mary Gaeddert
- Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Niels Halama
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
- Department of Translational Immunotherapy (D240), German Cancer Research Center, Heidelberg, Germany
- Helmholtz Institute for Translational Oncology, Mainz, Germany
| | - Stefan Meuer
- Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany
| | - Hans-Georg Kräusslich
- Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany
| | - Barbara Müller
- Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany
| | - Paul Schnitzler
- Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany
| | - Sylvia Parthé
- Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany
| | - Ralf Bartenschlager
- Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany
| | - Martina Gronkowski
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Jennifer Klemmer
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Michael Schmitt
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Peter Dreger
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Katharina Kriegsmann
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - Richard F Schlenk
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- NCT Trial Center, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
- Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Carsten Müller-Tidow
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
- National Center for Tumor Diseases, Heidelberg, Germany.
| |
Collapse
|
12
|
Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand M, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild M, Schmiedel S, Addo M, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski C, Celik C, Pohle T, Ruhe M, Kern W, Schmitt A, Schmitt M, Lorenz HM, Souto-Carneiro M, Halama N, Meurer S, Kräusslich HG, Müller B, Bartenschlager R, Gronkowski M, Klemmer J, Kriegsmann K, Schlenk R, Müller-Tidow C. 1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial. Open Forum Infect Dis 2022. [DOI: 10.1093/ofid/ofac492.980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Abstract
Background
Patients with hematological malignancy or other cancers as well as immunosuppression bear a high risk for severe COVID-19. Monoclonal antibodies (mAb) are efficient at early stages of the disease but may lose potency with new variants. Trials on plasma from convalescent donors in unselected patients have not shown clinical benefit. No randomized trials focussing on patients with underlying disease have been published.
Methods
We conducted an open-label, multicenter, randomized controlled trial to evaluate efficacy of plasma (CVP - convalescent or after vaccination) in patients with COVID-19 at high risk for adverse outcome in Germany. We assessed the effect of high-titer CVP (2 units from different donors, 238-337 ml each, on subsequent days). Patients with hematological or other malignancy (group 1), immunosuppression (group 2), age >50 and ≤75 years and lymphopenia and/or high D-dimers (group 3) or age >75 years (group 4) who were hospitalized with confirmed SARS-CoV-2 infection and with an oxygen saturation ≤94% were included. Primary outcome measure was time to clinical improvement on a seven-point ordinal scale, secondary outcome was mortality (Janssen et al. Trials 2020 Oct 6;21(1):828).
Results
Overall, 133 patients were randomized, 68 received CVP with an additional 10 patients as a crossover on day 10. Median age (range) was 68 years (39-95) in the CVP group and 70 (38-90) in controls. For the entire cohort, no significant difference was seen in time to improvement (median days: CVP 12.5 vs. control 18; HR 1.24 (95% confidence interval (CI) 0.83-1.85), p=0.29). Subgroup analysis (group 1+2) revealed shortened time to improvement (median days CVP 13 vs. control 32; HR 2.03 (95%CI 1.17-3.6), p=0.01) and mortality was reduced (mortality CVP n=6 (18%) vs. control n=10 (29%). No significant differences in time to improvement were observed in group 3 or 4 (HR 0.72 (95%CI 0.41-1.28), p=0.26). No relevant adverse events were observed.
Conclusion
CVP improves time to clinical improvement and mortality for COVID-19 patients with underlying hematological disease/cancer or other reasons of impaired immune response. Even with new variants, high-titer CVP may offer a widely available and inexpensive therapy option in high-risk groups.
Funding
BMBF FKZ 01KI20152; EudraCT 2020-001632-10.
Disclosures
Uta Merle, MD, Gilead: Sponsored congress travel and accommodation Markus Weigand, MD, Bbraun: Speakers fee/ad boards fee|Biotest: Speakers fee/ad boards fee|Eumedica: Speakers fee/ad boards fee|Gilead: Speakers fee/ad boards fee|MSD: Speakers fee/ad boards fee|Pfizer: Speakers fee/ad boards fee|Shionogi: Speakers fee/ad boards fee|SOBI: Speakers fee/ad boards fee Martin Bornhäuser, MD, Alexion: Honoraria|Jazz Pharmaceuticals: Honoraria|MSD: Honoraria|Novartis: Honoraria Nael Alakel, MD, Amgen: personal fee, travel grant|Gilead: personal fee, travel grant|MSD Sharp and Dohme GmbH: personal fee, travel grant|Pfizer: personal fee, travel grant Timo Wolf, MD, Gilead Sciences: Lecture fee, travel grant|Janssen Pharmaceuticals: Lecture fee, travel grant|Merck Sharp Dome: Lecture fee, travel grant Maria Vehreschild, Prof. Dr., 3M: speaker fee|Astellas: Advisor/Consultant|Astellas: speaker fee|biologische heilmittel heel gmbh: Grant/Research Support|BioNtech: Grant/Research Support|EUMEDICA: Advisor/Consultant|Farmak International Holding: Advisor/Consultant|Ferring: Advisor/Consultant|Ferring: Speaker fee|Gilead Sciences: Advisor/Consultant|Immunic AG: Advisor/Consultant|MaaT: Advisor/Consultant|Merck: Advisor/Consultant|Merck: speaker fee|MSD: Advisor/Consultant|MSD: Grant/Research Support|MSD: speaker fees|Pfizer: speaker fee|Roche Molecular Systems: Grant/Research Support|Roche Molecular Systems: speaker fees|SocraRTec R&D GmbH: Advisor/Consultant|Takeda California: Grant/Research Support Hanns-Martin Lorenz, MD, Abbvie: Advisor/Consultant|Abbvie: Honoraria|Actelion: Advisor/Consultant|Actelion: Honoraria|Alexion: Advisor/Consultant|Alexion: Honoraria|Amgen: Advisor/Consultant|Amgen: Grant/Research Support|Astra Zeneca: Advisor/Consultant|Astra Zeneca: Honoraria|Baxter: Advisor/Consultant|Baxter: Advisor/Consultant|Baxter: Honoraria|Baxter: Honoraria|Bayer Vital: Advisor/Consultant|Bayer Vital: Honoraria|Biogen: Advisor/Consultant|Biogen: Honoraria|BMS: Advisor/Consultant|BMS: Honoraria|Boehringer Ingelheim: Advisor/Consultant|Boehringer Ingelheim: Honoraria|Celgene: Advisor/Consultant|Celgene: Honoraria|Fresenius: Advisor/Consultant|Fresenius: Honoraria|Genzyme: Advisor/Consultant|Genzyme: Honoraria|Gilead/Galapagos: Advisor/Consultant|Gilead/Galapagos: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|Hexal: Advisor/Consultant|Hexal: Honoraria|Janssen-Cilag: Advisor/Consultant|Janssen-Cilag: Honoraria|Lilly: Advisor/Consultant|Lilly: Honoraria|Medac: Advisor/Consultant|Medac: Honoraria|MSD: Advisor/Consultant|MSD: Honoraria|Mundipharm: Advisor/Consultant|Mundipharm: Honoraria|Mylan: Advisor/Consultant|Mylan: Honoraria|Novartis: Advisor/Consultant|Novartis: Honoraria|octapharm: Advisor/Consultant|octapharm: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Honoraria|Roche/Chugai: Advisor/Consultant|Roche/Chugai: Honoraria|Sandoz: Advisor/Consultant|Sandoz: Honoraria|Sanofi: Advisor/Consultant|Sanofi: Honoraria|Shire: Advisor/Consultant|Shire: Honoraria|SOBI: Advisor/Consultant|SOBI: Honoraria|Thermo Fisher: Advisor/Consultant|Thermo Fisher: Honoraria|UCB: Advisor/Consultant|UCB: Honoraria.
Collapse
Affiliation(s)
- Claudia M Denkinger
- Division for Infectious Diseases and Tropical Medicine, University Hospital Heidelberg , Heidelberg, Baden-Wurttemberg , Germany
| | - Maike Janssen
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Ulrike Schäkel
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Julia Gall
- NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Albrecht Leo
- Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg , Heidelberg, Heidelberg, Baden-Wurttemberg , Germany
| | - Patrick Stelmach
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Stefan F Weber
- Division of Infectious Diseases and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Johannes Krisam
- Institute for Medical Biometry and Informatics, Ruprecht-Karls University Heidelberg , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Lukas Baumann
- Institute for Medical Biometry and Informatics, Ruprecht-Karls University Heidelberg , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Jacek Stermann
- Institute for Medical Biometry and Informatics, Ruprecht-Karls University Heidelberg , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Uta Merle
- Department of Internal Medicine IV, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Markus Weigand
- Department of Anaesthesiology, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Lars Bullinger
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic , Berlin, Germany, Berlin, Berlin , Germany
| | - Jens-Florian Schrezenmeier
- Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Campus Virchow Clinic , Berlin, Germany, Berlin, Berlin , Germany
| | - Martin Bornhäuser
- Department of Internal Medicine I, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden , Dresden, Germany, Dresden, Sachsen , Germany
| | - Nael Alakel
- Department of Internal Medicine I, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden , Dresden, Germany, Dresden, Sachsen , Germany
| | - Oliver Witzke
- Department of Infectious Diseases, West German Centre of Infectious Diseases, Universitymedicine Essen, University Duisburg-Essen , Germany, Essen, Nordrhein-Westfalen , Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt , Frankfurt am Main, Germany, Frankfurt, Hessen , Germany
| | - Maria Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt , Frankfurt am Main, Germany, Frankfurt, Hessen , Germany
| | - Stefan Schmiedel
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany, Hamburg, Hamburg , Germany
| | - Marylyn Addo
- I. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany, Hamburg, Hamburg , Germany
| | - Felix Herth
- Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Michael Kreuter
- Center for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, German Center for Lung Research(DZL) , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Phil-Robin Tepasse
- Department of Medicine B for Gastroenterology, Hepatology, Endocrinology, Clinical Infectiology , Münster, Germany, Münster, Nordrhein-Westfalen , Germany
| | - Bernd Hertenstein
- Medical Department I , Klinikum Bremen-Mitte, Bremen, Germany, Bremen, Bremen , Germany
| | - Mathias Hänel
- Department of Internal Medicine III , Klinikum Chemnitz gGmbH, Chemnitz, Germany, Chemnitz, Sachsen , Germany
| | - Anke Morgner
- Department of Internal Medicine III , Klinikum Chemnitz gGmbH, Chemnitz, Germany, Chemnitz, Sachsen , Germany
| | - Michael Kiehl
- Department I of Internal Medicine, Frankfurt (Oder) General Hospital , Frankfurt/Oder, Germany, Frankfurt a.d. Oder, Brandenburg , Germany
| | - Olaf Hopfer
- Department I of Internal Medicine, Frankfurt (Oder) General Hospital , Frankfurt/Oder, Germany, Frankfurt a.d. Oder, Brandenburg , Germany
| | - Mohammad-Amen Wattad
- Department of Hematology , Oncology, Palliative Care and Stem Cell Transplantation, Klinikum Hochsauerland GmbH, Meschede, Germany, Meschede, Nordrhein-Westfalen , Germany
| | - Carl Schimanski
- Department of Internal Medicine II , Klinikum Darmstadt GmbH, Darmstadt, Germany, Darmstadt, Hessen , Germany
| | - Cihan Celik
- Department of Internal Medicine II , Klinikum Darmstadt GmbH, Darmstadt, Germany, Darmstadt, Hessen , Germany
| | - Thorsten Pohle
- Department of Internal Medicine I , Klinikum Herford, Germany, Herford, Nordrhein-Westfalen , Germany
| | - Matthias Ruhe
- Department of Internal Medicine I , Klinikum Herford, Germany, Herford, Nordrhein-Westfalen , Germany
| | - Winfried Kern
- Department of Medicine II, Division of Infectious Diseases and Travel Medicine, University Medical Centre Freiburg , Freiburg, Germany, Freiburg, Baden-Wurttemberg , Germany
| | - Anita Schmitt
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Michael Schmitt
- University of Heidelberg , Heidelberg, Baden-Wurttemberg , Germany
| | - Hanns-Martin Lorenz
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Margarida Souto-Carneiro
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Niels Halama
- Department of Medical Oncology and Internal Medicine V, National Center for Tumor Diseases (NCT), University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Stefan Meurer
- Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg , Heidelberg, Heidelberg, Baden-Wurttemberg , Germany
| | - Hans-Georg Kräusslich
- Department of Infectious Diseases, Virology, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Barbara Müller
- Department of Infectious Diseases, Virology, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Ralf Bartenschlager
- Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Martina Gronkowski
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Jennifer Klemmer
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Katharina Kriegsmann
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Richard Schlenk
- NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| | - Carsten Müller-Tidow
- Department of Internal Medicine V, Heidelberg University Hospital , Heidelberg, Germany, Heidelberg, Baden-Wurttemberg , Germany
| |
Collapse
|
13
|
Levin I, Wolf T, Asselmann D, Bar O, Ben Ayoun D, Antolin A, Cohen A. Artificial Intelligence Vision Based Analysis and Key Steps Identification Feasibility Study in Laparoscopic Hysterectomies. J Minim Invasive Gynecol 2022. [DOI: 10.1016/j.jmig.2022.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Althueser L, Andrieu B, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Bui TK, Cai C, Capelli C, Cardoso JMR, Cichon D, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Eitel K, Elykov A, Farrell S, Ferella AD, Ferrari C, Fischer H, Fulgione W, Gaemers P, Gaior R, Gallo Rosso A, Galloway M, Gao F, Gardner R, Glade-Beucke R, Grandi L, Grigat J, Guida M, Hammann R, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kara M, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Kuger F, Landsman H, Lang RF, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Loizeau J, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Paschos P, Peres R, Peters C, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulte P, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Stephen J, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu D, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhong M, Zhu T. Search for New Physics in Electronic Recoil Data from XENONnT. Phys Rev Lett 2022; 129:161805. [PMID: 36306777 DOI: 10.1103/physrevlett.129.161805] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 09/21/2022] [Indexed: 06/16/2023]
Abstract
We report on a blinded analysis of low-energy electronic recoil data from the first science run of the XENONnT dark matter experiment. Novel subsystems and the increased 5.9 ton liquid xenon target reduced the background in the (1, 30) keV search region to (15.8±1.3) events/(ton×year×keV), the lowest ever achieved in a dark matter detector and ∼5 times lower than in XENON1T. With an exposure of 1.16 ton-years, we observe no excess above background and set stringent new limits on solar axions, an enhanced neutrino magnetic moment, and bosonic dark matter.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - B Andrieu
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - F Arneodo
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - T K Bui
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Cai
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - J J Cuenca-García
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Di Giovanni
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - K Eitel
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - C Ferrari
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - A Gallo Rosso
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - R Gardner
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Guida
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Hammann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Joy
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - M Kara
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - F Kuger
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Li
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - J Loizeau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - F Lombardi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - F Marignetti
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, CNRS/IN2P3, 75005 Paris, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini," University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Müller
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - B Paetsch
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - P Paschos
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - C Peters
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | | | - S Reichard
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - I Sarnoff
- New York University Abu Dhabi-Center for Astro, Particle and Planetary Physics, Abu Dhabi, United Arab Emirates
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - P Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Shi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Stephen
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - P-L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes Université, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Xu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| |
Collapse
|
15
|
Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S, Marschalek R, Herrmann E, Helfritz FA, Wolf T, Goetsch U, Ciesek S. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine 2022; 82:104158. [PMID: 35834885 DOI: 10.1101/2021.12.07.21267432] [Citation(s) in RCA: 157] [Impact Index Per Article: 78.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2022] [Revised: 06/23/2022] [Accepted: 06/28/2022] [Indexed: 05/21/2023] Open
Abstract
BACKGROUND In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based on Wuhan-Hu 1 isolate of SARS-CoV-2, is reduced, leading to breakthrough infections. Efficacy of monoclonal antibody therapy is also likely impaired. METHODS In our in vitro study using A549-AT cells constitutively expressing ACE2 and TMPRSS2, we determined and compared the neutralizing capacity of vaccine-elicited sera, convalescent sera and monoclonal antibodies against authentic SARS-CoV-2 Omicron BA.1 and BA.2 compared with Delta. FINDINGS Almost no neutralisation of Omicron BA.1 and BA.2 was observed using sera from individuals vaccinated with two doses 6 months earlier, regardless of the type of vaccine taken. Shortly after the booster dose, most sera from triple BNT162b2-vaccinated individuals were able to neutralise both Omicron variants. In line with waning antibody levels three months after the booster, only weak residual neutralisation was observed for BA.1 (26%, n = 34, 0 median NT50) and BA.2 (44%, n = 34, 0 median NT50). In addition, BA.1 but not BA.2 was resistant to the neutralising monoclonal antibodies casirivimab/imdevimab, while BA.2 exhibited almost a complete evasion from the neutralisation induced by sotrovimab. INTERPRETATION Both SARS-CoV-2 Omicron subvariants BA.1 and BA.2 escape antibody-mediated neutralisation elicited by vaccination, previous infection with SARS-CoV-2, and monoclonal antibodies. Waning immunity renders the majority of tested sera obtained three months after booster vaccination negative in BA.1 and BA.2 neutralisation. Omicron subvariant specific resistance to the monoclonal antibodies casirivimab/imdevimab and sotrovimab emphasizes the importance of genotype-surveillance and guided application. FUNDING This study was supported in part by the Goethe-Corona-Fund of the Goethe University Frankfurt (M.W.) and the Federal Ministry of Education and Research (COVIDready; grant 02WRS1621C (M.W.).
Collapse
Affiliation(s)
- Alexander Wilhelm
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Marek Widera
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.
| | - Katharina Grikscheit
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Tuna Toptan
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Barbara Schenk
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Christiane Pallas
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Melinda Metzler
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Niko Kohmer
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Sebastian Hoehl
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Rolf Marschalek
- Institute of Pharmaceutical Biology, Goethe University, Frankfurt am Main, Germany
| | - Eva Herrmann
- Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, 60596 Frankfurt, Germany
| | - Fabian A Helfritz
- Bürgerhospital Frankfurt, Nibelungenallee 37-41, 60318 Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Udo Goetsch
- Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany
| | - Sandra Ciesek
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; German Centre for Infection Research (DZIF), partner site Frankfurt, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology, Branch Translational Medicine and Pharmacology, 60596 Frankfurt am Main, Germany.
| |
Collapse
|
16
|
Johnson MG, Puenpatom A, Moncada PA, Burgess L, Duke ER, Ohmagari N, Wolf T, Bassetti M, Bhagani S, Ghosn J, Zhang Y, Wan H, Williams-Diaz A, Brown ML, Paschke A, De Anda C. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial. Ann Intern Med 2022; 175:1126-1134. [PMID: 35667065 PMCID: PMC9186515 DOI: 10.7326/m22-0729] [Citation(s) in RCA: 39] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease. OBJECTIVE To identify other potential clinical benefits of molnupiravir versus placebo. DESIGN Secondary analysis of the randomized, double-blind, placebo-controlled phase 3 component of MOVe-OUT. (ClinicalTrials.gov: NCT04575597). SETTING 107 sites globally. PARTICIPANTS 1433 nonhospitalized adults aged 18 years or older with mild to moderate COVID-19. INTERVENTION Molnupiravir, 800 mg, or placebo every 12 hours for 5 days. MEASUREMENTS Changes from baseline in C-reactive protein (CRP) concentration and oxygen saturation (Spo 2), need for respiratory interventions (including invasive mechanical ventilation), and need for medical services in all randomly assigned participants through day 29, and need for respiratory interventions and time to discharge in the subgroup of participants who were hospitalized after randomization. RESULTS Participants receiving molnupiravir showed faster normalization of CRP and Spo 2, with improvements observed on day 3 of therapy, compared with placebo. Molnupiravir-treated participants had a decreased need for respiratory interventions versus placebo-treated participants (relative risk reduction [RRR], 34.3% [95% CI, 4.3% to 54.9%]), with similar findings in participants who were hospitalized after randomization (RRR, 21.3% [CI, 0.2% to 38.0%]). Hospitalized participants who received molnupiravir were discharged a median of 3 days before those who received placebo. Acute care visits (7.2% vs. 10.6%; RRR, 32.1% [CI, 4.4% to 51.7%]) and COVID-19-related acute care visits (6.6% vs. 10.0%; RRR, 33.8% [CI, 5.6% to 53.6%]) were less frequent in molnupiravir- versus placebo-treated participants. LIMITATIONS Some analyses were performed post hoc. Longer-term benefits of molnupiravir therapy were not evaluated. Participants were not immunized against SARS-CoV-2. CONCLUSION The findings suggest there are additional important clinical benefits of molnupiravir beyond reduction in hospitalization or death. PRIMARY FUNDING SOURCE Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Collapse
Affiliation(s)
- Matthew G Johnson
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Amy Puenpatom
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | | | - Lesley Burgess
- TREAD Research, Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and Stellenbosch University, Parow, South Africa (L.B.)
| | - Elizabeth R Duke
- Fred Hutchinson Cancer Research Center, Seattle, Washington (E.R.D.)
| | - Norio Ohmagari
- National Center for Global Health and Medicine, Tokyo, Japan (N.O.)
| | - Timo Wolf
- Universitätsklinikum Frankfurt, Frankfurt am Main, Germany (T.W.)
| | - Matteo Bassetti
- IRCCS Ospedale Policlinico San Martino, and Department of Health Sciences, University of Genoa, Genova, Italy (M.B.)
| | - Sanjay Bhagani
- Royal Free London NHS Foundation Trust, London, United Kingdom (S.B.)
| | - Jade Ghosn
- AP-HP. Nord, Hôpital Bichat - Claude Bernard, and Université Paris Cité, INSERM UMR 1137 IAME, Paris, France (J.G.)
| | - Ying Zhang
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Hong Wan
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Angela Williams-Diaz
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Michelle L Brown
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Amanda Paschke
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| | - Carisa De Anda
- Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
| |
Collapse
|
17
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare JR, Antochi VC, Antón Martin D, Arneodo F, Baudis L, Baxter AL, Bellagamba L, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Colijn AP, Conrad J, Cuenca-García JJ, Cussonneau JP, D'Andrea V, Decowski MP, Gangi PD, Pede SD, Giovanni AD, Stefano RD, Diglio S, Elykov A, Farrell S, Ferella AD, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hiraide K, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Li I, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Ni K, Oberlack U, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, Dos Santos JMF, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Lavina LS, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Westermann J, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis JP, Laubenstein M, Nisi S. Material radiopurity control in the XENONnT experiment. Eur Phys J C Part Fields 2022; 82:599. [PMID: 35821975 PMCID: PMC9270421 DOI: 10.1140/epjc/s10052-022-10345-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 04/19/2022] [Indexed: 11/18/2022]
Abstract
The selection of low-radioactive construction materials is of the utmost importance for rare-event searches and thus critical to the XENONnT experiment. Results of an extensive radioassay program are reported, in which material samples have been screened with gamma-ray spectroscopy, mass spectrometry, and \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn emanation measurements. Furthermore, the cleanliness procedures applied to remove or mitigate surface contamination of detector materials are described. Screening results, used as inputs for a XENONnT Monte Carlo simulation, predict a reduction of materials background (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\sim $$\end{document}∼17%) with respect to its predecessor XENON1T. Through radon emanation measurements, the expected \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{222}$$\end{document}222Rn activity concentration in XENONnT is determined to be 4.2 (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$^{+0.5}_{-0.7}$$\end{document}-0.7+0.5) \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$\upmu $$\end{document}μBq/kg, a factor three lower with respect to XENON1T. This radon concentration will be further suppressed by means of the novel radon distillation system.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, NY 10027 USA
| | - K Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Ahmed Maouloud
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Alfonsi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - D Antón Martin
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - F Arneodo
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - A L Baxter
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - R Biondi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - A Bismark
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - A Brown
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands.,Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Bruno
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates.,SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - B Cimmino
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands.,Institute for Subatomic Physics, Utrecht University, Utrecht, The Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - J J Cuenca-García
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - V D'Andrea
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Di Pede
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - A Di Giovanni
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Farrell
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - A D Ferella
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy.,INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, The Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - F Gao
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing, 100084 China
| | - R Glade-Beucke
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Grandi
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - J Grigat
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A Higuera
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Hiraide
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - J Jakob
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - P Kavrigin
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan.,Institute for Advanced Research, Nagoya University, Nagoya, Aichi, 464-8601 Japan
| | - M Kobayashi
- Physics Department, Columbia University, New York, NY 10027 USA.,Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602 Japan
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - A Kopec
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - I Li
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - K Liu
- Department of Physics and Center for High Energy Physics, Tsinghua University, Beijing, 100084 China
| | - F Lombardi
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany.,LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - J Long
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal.,Coimbra Polytechnic-ISEC, 3030-199 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - C Macolino
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy.,Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- Particle and Planetary Physics, New York University Abu Dhabi-Center for Astro, Abu Dhabi, United Arab Emirates
| | - A Manfredini
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - F Marignetti
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Masson
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France.,Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - S Mastroianni
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Naples, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501 Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501 Japan
| | - A Molinario
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - K Morå
- Physics Department, Columbia University, New York, NY 10027 USA
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - M Murra
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - J Pienaar
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, IN 47907 USA
| | - D Ramírez García
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Reichard
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland.,Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - L Sanchez
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Scotto Lavina
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany.,Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - E Shockley
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - P L Tan
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, 10691 Stockholm, Sweden
| | - A Terliuk
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C Therreau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, 44307 Nantes, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Turin, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, TX 77005 USA
| | - F Tönnies
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zurich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA+, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Westermann
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - C Wittweg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Z Xu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Yamashita
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Higashi-Mozumi, Kamioka Hida, Gifu 506-1205 Japan
| | - L Yang
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - J Ye
- Physics Department, Columbia University, New York, NY 10027 USA
| | - L Yuan
- Department of Physics and Kavli Institute for Cosmological Physics, University of Chicago, Chicago, IL 60637 USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy.,INFN, Sez. di Ferrara and Dip. di Fisica e Scienze della Terra, Università di Ferrara, via G. Saragat 1, Edificio C, 44122 Ferrara, Italy
| | - Y Zhang
- Physics Department, Columbia University, New York, NY 10027 USA
| | - M Zhong
- Department of Physics, University of California San Diego, La Jolla, CA 92093 USA
| | - T Zhu
- Physics Department, Columbia University, New York, NY 10027 USA
| | - J P Zopounidis
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, 75005 Paris, France
| | | | - M Laubenstein
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - S Nisi
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| |
Collapse
|
18
|
Aprile E, Abe K, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Angelino E, Angevaare J, Antochi V, Antón Martin D, Arneodo F, Baudis L, Baxter A, Bellagamba L, Bernard A, Biondi R, Bismark A, Brown A, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso J, Cichon D, Cimmino B, Clark M, Colijn A, Conrad J, Cuenca-García J, Cussonneau J, D’Andrea V, Decowski M, Di Gangi P, Di Pede S, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Farrell S, Ferella A, Fischer H, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Glade-Beucke R, Grandi L, Grigat J, Higuera A, Hils C, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Jakob J, Joerg F, Joy A, Kato N, Kavrigin P, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang R, Levinson L, Li I, Li S, Liang S, Lindemann S, Lindner M, Liu K, Lombardi F, Long J, Lopes J, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Masson E, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Moriyama S, Morå K, Mosbacher Y, Murra M, Müller J, Ni K, Oberlack U, Paetsch B, Palacio J, Peres R, Pienaar J, Pierre M, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Sanchez L, dos Santos J, Sarnoff I, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shi S, Shockley E, Silva M, Simgen H, Takeda A, Tan PL, Terliuk A, Thers D, Toschi F, Trinchero G, Tunnell C, Tönnies F, Valerius K, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu Z, Yamashita M, Yang L, Ye J, Yuan L, Zavattini G, Zhang Y, Zhong M, Zhu T, Zopounidis J. Emission of single and few electrons in XENON1T and limits on light dark matter. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.022001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
19
|
Paris G, Heidepriem J, Tsouka A, Liu Y, Mattes DS, Pinzón Martín S, Dallabernardina P, Mende M, Lindner C, Wawrzinek R, Rademacher C, Seeberger PH, Breitling F, Bischoff FR, Wolf T, Loeffler FF. Automated Laser-Transfer Synthesis of High-Density Microarrays for Infectious Disease Screening. Adv Mater 2022; 34:e2200359. [PMID: 35429012 DOI: 10.1002/adma.202200359] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 03/23/2022] [Indexed: 06/14/2023]
Abstract
Laser-induced forward transfer (LIFT) is a rapid laser-patterning technique for high-throughput combinatorial synthesis directly on glass slides. A lack of automation and precision limits LIFT applications to simple proof-of-concept syntheses of fewer than 100 compounds. Here, an automated synthesis instrument is reported that combines laser transfer and robotics for parallel synthesis in a microarray format with up to 10 000 individual reactions cm- 2 . An optimized pipeline for amide bond formation is the basis for preparing complex peptide microarrays with thousands of different sequences in high yield with high reproducibility. The resulting peptide arrays are of higher quality than commercial peptide arrays. More than 4800 15-residue peptides resembling the entire Ebola virus proteome on a microarray are synthesized to study the antibody response of an Ebola virus infection survivor. Known and unknown epitopes that serve now as a basis for Ebola diagnostic development are identified. The versatility and precision of the synthesizer is demonstrated by in situ synthesis of fluorescent molecules via Schiff base reaction and multi-step patterning of precisely definable amounts of fluorophores. This automated laser transfer synthesis approach opens new avenues for high-throughput chemical synthesis and biological screening.
Collapse
Affiliation(s)
- Grigori Paris
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Department of System Dynamics and Friction Physics, Institute of Mechanics, Technical University of Berlin, Str. des 17. Juni 135, 10623, Berlin, Germany
| | - Jasmin Heidepriem
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany
| | - Alexandra Tsouka
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany
| | - Yuxin Liu
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany
| | - Daniela S Mattes
- Institute of Microstructure Technology, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafe, Germany
| | - Sandra Pinzón Martín
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany
| | - Pietro Dallabernardina
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
| | - Marco Mende
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
| | - Celina Lindner
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
| | - Robert Wawrzinek
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
| | - Christoph Rademacher
- Department of Pharmaceutical Sciences, University of Vienna, Althanstr. 14, Vienna, 1090, Austria
- Department of Microbiology and Immunobiology, Max F. Perutz Laboratories GmbH, Dr.-Bohr-Gasse 9, Vienna, 1030, Austria
| | - Peter H Seeberger
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany
| | - Frank Breitling
- Institute of Microstructure Technology, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, 76344, Eggenstein-Leopoldshafe, Germany
| | - Frank Ralf Bischoff
- Department of Functional Genome Analysis, German Cancer Research Center, Im Neuenheimer Feld 580, 69120, Heidelberg, Germany
| | - Timo Wolf
- Infectious Diseases Unit, Department of Medicine, Goethe University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Felix F Loeffler
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Muehlenberg 1, 14476, Potsdam, Germany
| |
Collapse
|
20
|
Geller M, Slater R, Graham‐Williams E, Wolf T, Spriet M, Berryhill E, Skipper L, Aleman M. Imaging of equine septic discospondylitis using MRI, CT and post‐mortem radiographs. EQUINE VET EDUC 2022. [DOI: 10.1111/eve.13620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M. Geller
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - R. Slater
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - E. Graham‐Williams
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - T. Wolf
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - M. Spriet
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - E. Berryhill
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - L. Skipper
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| | - M. Aleman
- University of California Davis California USA
- The William R. Pritchard Veterinary Medical Teaching Hospital Davis California USA
| |
Collapse
|
21
|
Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, Esser-Nobis K, Filomena A, Mahler V, Maier TJ, Stephan C. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol 2022; 146:105052. [PMID: 34920374 PMCID: PMC8642248 DOI: 10.1016/j.jcv.2021.105052] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 10/23/2021] [Accepted: 12/02/2021] [Indexed: 12/18/2022]
Abstract
BACKGROUND Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration. METHODS Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples. RESULTS Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%). CONCLUSION Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.
Collapse
Affiliation(s)
| | | | - Timo Wolf
- University Hospital Frankfurt - Department of Infectious Diseases and HIV, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Yascha Khodamoradi
- University Hospital Frankfurt - Department of Infectious Diseases and HIV, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Carla Bellinghausen
- University Hospital Frankfurt - Department of Respiratory Medicine and Allergology, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Michael Sonntagbauer
- University Hospital Frankfurt - Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany
| | | | - Angela Filomena
- Paul-Ehrlich-Institute, IVD Testing Laboratory, Langen, Germany
| | - Vera Mahler
- Paul-Ehrlich-Institute, Division Allergology, Langen, Germany
| | - Thorsten Jürgen Maier
- Paul-Ehrlich-Institute, Division Safety of Medicinal Products and Medical Devices, Langen, Germany
| | - Christoph Stephan
- University Hospital Frankfurt - Department of Infectious Diseases and HIV, Goethe University Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
22
|
Weiss R, Guchlerner L, Weissgerber T, Filmann N, Haake B, Zacharowski K, Wolf T, Wicker S, Kempf VAJ, Ciesek S, Stöver T, Diensthuber M. Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception. J Occup Med Toxicol 2021; 16:43. [PMID: 34592994 PMCID: PMC8481762 DOI: 10.1186/s12995-021-00334-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 09/21/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Due to the coronavirus disease 2019 (COVID-19) pandemic, interventions in the upper airways are considered high-risk procedures for otolaryngologists and their colleagues. The purpose of this study was to evaluate limitations in hearing and communication when using a powered air-purifying respirator (PAPR) system to protect against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) transmission and to assess the benefit of a headset. METHODS Acoustic properties of the PAPR system were measured using a head and torso simulator. Audiological tests (tone audiometry, Freiburg speech test, Oldenburg sentence test (OLSA)) were performed in normal-hearing subjects (n = 10) to assess hearing with PAPR. The audiological test setup also included simulation of conditions in which the target speaker used either a PAPR, a filtering face piece (FFP) 3 respirator, or a surgical face mask. RESULTS Audiological measurements revealed that sound insulation by the PAPR headtop and noise, generated by the blower-assisted respiratory protection system, resulted in significantly deteriorated hearing thresholds (4.0 ± 7.2 dB hearing level (HL) vs. 49.2 ± 11.0 dB HL, p < 0.001) and speech recognition scores in quiet (100.0 ± 0.0% vs. 2.5 ± 4.2%, p < 0.001; OLSA: 20.8 ± 1.8 dB vs. 61.0 ± 3.3 dB SPL, p < 0.001) when compared to hearing without PAPR. Hearing with PAPR was significantly improved when the subjects were equipped with an in-ear headset (p < 0.001). Sound attenuation by FFP3 respirators and surgical face masks had no clinically relevant impact on speech perception. CONCLUSIONS The PAPR system evaluated here can be considered for high-risk procedures in SARS-CoV-2-positive patients, provided that hearing and communication of the surgical team are optimized by the additional use of a headset.
Collapse
Affiliation(s)
- Roxanne Weiss
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Leon Guchlerner
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Tobias Weissgerber
- Division of Audiological Acoustics, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Natalie Filmann
- Institute of Biostatistics and Mathematical Modelling, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Birgit Haake
- Department of Anesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Kai Zacharowski
- Department of Anesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Timo Wolf
- Department of Internal Medicine II, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Sabine Wicker
- Occupational Health Service, University Hospital Frankfurt Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Volkhard A J Kempf
- Institute for Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany
- University Center of Competence for Infection Control of the State of Hesse, Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany
| | - Sandra Ciesek
- Institute of Medical Virology, University Hospital Frankfurt, Goethe University, Paul-Ehrlich-Str. 40, 60596, Frankfurt/M, Germany
- German Centre for Infection Research, External partner site Frankfurt, Frankfurt/M, Germany
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, Frankfurt, Germany
| | - Timo Stöver
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany
| | - Marc Diensthuber
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany.
| |
Collapse
|
23
|
Wilhelm A, Toptan T, Pallas C, Wolf T, Goetsch U, Gottschalk R, Vehreschild MJGT, Ciesek S, Widera M. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses 2021; 13:v13091693. [PMID: 34578275 DOI: 10.1101/2021.08.09.21261704] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 08/22/2021] [Accepted: 08/22/2021] [Indexed: 05/24/2023] Open
Abstract
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
Collapse
Affiliation(s)
- Alexander Wilhelm
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Tuna Toptan
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Christiane Pallas
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| | - Udo Goetsch
- Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany
| | - Rene Gottschalk
- Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
| | - Sandra Ciesek
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
- Branch Translational Medicine and Pharmacology, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), 60596 Frankfurt am Main, Germany
| | - Marek Widera
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
| |
Collapse
|
24
|
Wilhelm A, Toptan T, Pallas C, Wolf T, Goetsch U, Gottschalk R, Vehreschild MJGT, Ciesek S, Widera M. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses 2021; 13:1693. [PMID: 34578275 PMCID: PMC8473269 DOI: 10.3390/v13091693] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 08/22/2021] [Accepted: 08/22/2021] [Indexed: 12/23/2022] Open
Abstract
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
Collapse
Affiliation(s)
- Alexander Wilhelm
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (A.W.); (T.T.); (C.P.); (S.C.)
| | - Tuna Toptan
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (A.W.); (T.T.); (C.P.); (S.C.)
| | - Christiane Pallas
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (A.W.); (T.T.); (C.P.); (S.C.)
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (T.W.); (M.J.G.T.V.)
| | - Udo Goetsch
- Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany; (U.G.); (R.G.)
| | - Rene Gottschalk
- Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany; (U.G.); (R.G.)
| | - Maria J. G. T. Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (T.W.); (M.J.G.T.V.)
- University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany
- German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
| | - Sandra Ciesek
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (A.W.); (T.T.); (C.P.); (S.C.)
- German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
- Branch Translational Medicine and Pharmacology, Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), 60596 Frankfurt am Main, Germany
| | - Marek Widera
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany; (A.W.); (T.T.); (C.P.); (S.C.)
| |
Collapse
|
25
|
Wiecki P, Frachet M, Haghighirad AA, Wolf T, Meingast C, Heid R, Böhmer AE. Emerging symmetric strain response and weakening nematic fluctuations in strongly hole-doped iron-based superconductors. Nat Commun 2021; 12:4824. [PMID: 34376670 PMCID: PMC8355183 DOI: 10.1038/s41467-021-25121-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 07/25/2021] [Indexed: 11/18/2022] Open
Abstract
Electronic nematicity is often found in unconventional superconductors, suggesting its relevance for electronic pairing. In the strongly hole-doped iron-based superconductors, the symmetry channel and strength of the nematic fluctuations, as well as the possible presence of long-range nematic order, remain controversial. Here, we address these questions using transport measurements under elastic strain. By decomposing the strain response into the appropriate symmetry channels, we demonstrate the emergence of a giant in-plane symmetric contribution, associated with the growth of both strong electronic correlations and the sensitivity of these correlations to strain. We find weakened remnants of the nematic fluctuations that are present at optimal doping, but no change in the symmetry channel of nematic fluctuations with hole doping. Furthermore, we find no indication of a nematic-ordered state in the AFe2As2 (A = K, Rb, Cs) superconductors. These results revise the current understanding of nematicity in hole-doped iron-based superconductors.
Collapse
Affiliation(s)
- P Wiecki
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - M Frachet
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - A-A Haghighirad
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - T Wolf
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - C Meingast
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - R Heid
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany
| | - A E Böhmer
- Karlsruhe Institute of Technology, Institute for Quantum Materials and Technologies, Karlsruhe, Germany.
- Institut für Experimentalphysik IV, Ruhr-Universität Bochum, Bochum, Germany.
| |
Collapse
|
26
|
Kann G, Owasil J, Kuczka K, Haberl A, Wolf T, Khaykin P, Harder S, Stephan C, von Hentig N. Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study. HIV AIDS (Auckl) 2021; 13:789-800. [PMID: 34393518 PMCID: PMC8354741 DOI: 10.2147/hiv.s262282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 11/13/2020] [Indexed: 11/23/2022]
Abstract
Background In the past, protease inhibitors (PIs) and the reverse transcriptase inhibitor abacavir were identified increasing the risk for thromboembolic complications and cardiovascular events (CVE) of HIV infected patients taking a combination antiretroviral therapy (cART). Results of the previous HIV-PLA I-study lead to the assumption that platelet activation could play a substantial role in increasing CVE risks. Methods The open label, monocentric HIV-PLA II-study investigated HIV-1-infected, therapy-naïve adults (n=45) starting with cART, consisting either of boosted PI (atazanavir, n= 6, darunavir, n=11), NNRTI (efavirenz, n=14) or integrase inhibitor (raltegravir, n=14), each plus tenofovir/emtricitabine co-medication. Main exclusion criteria were tobacco smoking, the intake of NSAIDs or abacavir or past CVE. Platelet adhesive molecule p-selectin (CD62P) and FITC anti-human Integrin α-IIb/Integrin β-3 (CD41/CD61) antibody (PAC-1) binding, monocyte CD11b/monocyte-associated CD41 expression and the endogenous thrombin potential (ETP) were assessed ex vivo-in vitro at baseline, weeks 4, 12 and 24. Therapy regimens were blinded to the investigators for laboratory and statistical analyses. Results CD11b and ETP showed no significant changes or differences between all study groups. In contrast, the mean + SD mean fluorescence units (MFI) of CD62P and PAC-1 increased significantly in patients taking PI, indicating an enhanced potential for thrombocyte activation and aggregation. Conclusion CD62P expression, detecting the ɑ-platelet degranulation of pro-inflammatory and pro-thrombotic factors and adhesive proteins, and PAC-1 expression, representing a marker for conformation changes of the GIIb/IIIa receptor, increased significantly in patients taking HIV protease inhibitors. The findings of this study revealed a yet unknown pathway of platelet activation, possibly contributing to the increased risk for CVE under HIV protease inhibitor containing cART. Clinical Trial Registration No. DRKS00000288.
Collapse
Affiliation(s)
- Gerrit Kann
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Junaid Owasil
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Karina Kuczka
- Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Annette Haberl
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Pavel Khaykin
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Sebastian Harder
- Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Christoph Stephan
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Nils von Hentig
- HIVCENTER, Medical HIV Treatment and Research Unit, Johann Wolfgang Goethe University Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
27
|
Herstein JJ, Lowe JJ, Wolf T, Vasoo S, Leo YS, Chin B, Shen Y, Hewlett AL, Lawler JV. Leveraging a preexisting global infectious disease network for local decision-making during a pandemic. Clin Infect Dis 2021; 74:729-733. [PMID: 34318871 PMCID: PMC8406886 DOI: 10.1093/cid/ciab660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Indexed: 12/15/2022] Open
Abstract
Emerging infectious disease epidemics require a rapid response from health systems; however, evidence-based consensus guidelines are generally absent early in the course of events. Formed in 2017 by five high-level isolation units spanning three continents, the experience of the Global Infectious Disease Preparedness Network (GIDPN) early in the course of COVID-19 provides a model for accelerating best practice development and improving decision-making in health emergencies. The network served as a platform for real-time, open and transparent information-sharing during unknowns of an active outbreak by clinicians caring for patients, by researchers conducting clinical trials and transmission and infection prevention studies, and by teams advising local and national policymakers. Shared knowledge led to earlier adoption of some treatment modalities as compared to most peer institutions and to implementation of protocols prior to incorporation into national guidelines. GIDPN and similar networks are integral in enhancing preparedness for and response to future epidemics/pandemics.
Collapse
Affiliation(s)
- Jocelyn J Herstein
- Department of Environmental, Agricultural, and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
| | - John J Lowe
- Department of Environmental, Agricultural, and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
| | - Timo Wolf
- Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Shawn Vasoo
- National Centre for Infectious Diseases, Singapore.,Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
| | - Yee Sin Leo
- National Centre for Infectious Diseases, Singapore.,Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
| | - BumSik Chin
- Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea
| | - Yinzhong Shen
- Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
| | - Angela L Hewlett
- Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| | - James V Lawler
- Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
| |
Collapse
|
28
|
Maul K, Fieblinger D, Heppenheimer A, Kreutz J, Liebsch M, Luch A, Pirow R, Poth A, Strauch P, Dony E, Schulz M, Wolf T, Reisinger K. Validation of the hen's egg test for micronucleus induction (HETMN): Detailed protocol including scoring atlas, historical control data and statistical analysis. Mutagenesis 2021; 37:76-88. [PMID: 34313790 PMCID: PMC9071076 DOI: 10.1093/mutage/geab026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 08/03/2021] [Indexed: 11/14/2022] Open
Abstract
A validation exercise of the hen's egg test for micronucleus induction (HET-MN) was finalised with a very good predictivity based on the analysis of micronuclei in peripheral erythrocytes of fertilised chicken eggs [1]. For transparency reasons this complementary publication provides further details on the assay especially as this was the first validation study in the field of genotoxicity testing involving the use of chicken eggs. Thus, the experimental protocol is described in detail and is complemented by a scoring atlas for microscopic analysis of blood cells. In addition, general characteristics of the test system, which is able to mirror the systemic availability of test compounds, are delineated: the test compound passes the egg membrane and is taken up by the blood vessels of the underlying chorioallantoic membrane. Subsequently, it is distributed by the circulating blood, metabolised by the developing liver and the yolk sac membrane, and finally excreted into the allantois, a bladder equivalent. In specific, the suitability of the test system for genotoxicity testing is shown by, inter alia, a low background DNA damage in a comprehensive historical control database. In addition, the state-of-the-art statistical method used to evaluate obtained data is delineated. It combines laboratory-specific effect threshold with the Umbrella-Williams test a statistical model also of interest for other genotoxicity test methods.
Collapse
Affiliation(s)
- K Maul
- German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany
| | - D Fieblinger
- German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany
| | - A Heppenheimer
- ICCR-Roßdorf GmbH (former: Harlan Cytotest Cell Research, Envigo CRS), Roßdorf, Germany
| | - J Kreutz
- Henkel AG & Co KGaA, Duesseldorf, Germany
| | - M Liebsch
- German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany
| | - A Luch
- German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany
| | - R Pirow
- German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany
| | - A Poth
- ICCR-Roßdorf GmbH (former: Harlan Cytotest Cell Research, Envigo CRS), Roßdorf, Germany
| | - P Strauch
- ICCR-Roßdorf GmbH (former: Harlan Cytotest Cell Research, Envigo CRS), Roßdorf, Germany
| | - E Dony
- ICCR-Roßdorf GmbH (former: Harlan Cytotest Cell Research, Envigo CRS), Roßdorf, Germany
| | - M Schulz
- ICCR-Roßdorf GmbH (former: Harlan Cytotest Cell Research, Envigo CRS), Roßdorf, Germany
| | - T Wolf
- University of Osnabrueck, Osnabrueck, Germany
| | | |
Collapse
|
29
|
Arendt C, De Leuw P, Haberl A, Kann G, Wolf T, Stephan C, Schuettfort G, Arcari L, Vasquez M, Albrecht M, Escher F, Vogl T, Zeiher A, Nagel E, Puntmann V. Outcomes of cardiovascular magnetic resonance imaging in people living with HIV. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeab090.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background/Introduction
People living with human immunodeficiency virus (HIV, PLWH) are at increased risk of cardiovascular disease (CVD). HIV infection and accelerated traditional risk factors due to highly-active antiretroviral therapy (HAART) are proposed mechanisms for increased rate of heart failure (HF). The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood.
Purpose
To examine prognostic relationships of cardiac imaging measures with cardiovascular outcome in PLWH on HAART.
Methods
This is a prospective observational longitudinal study using cardiac magnetic resonance (CMR) imaging in consecutive PLHWH on long-term HAART who were screened for underlying CVD and followed up clinically for adjudicated adverse cardiovascular events (cardiovascular mortality, non-fatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization). Imaging protocol included routine assessment of cardiac volumes and function, scar by late gadolinium enhancement, myocardial perfusion and native T1 /T2 mapping. Time-to-event analysis was performed from the index CMR exam to the first single event per patient Systematic risk scores for CVD (Framingham risk score (FRS), Data Collection on Adverse effects of anti-HIV Drugs score, D:A:D and MAGGIC integer score) were calculated using original online calculators.
Results
156 participants (males 62%, 50 [42-57] years of age) were included. 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 non-fatal acute myocardial infarction, 1 appropriate device discharge and 16 HF hospitalizations) during a median follow-up of 13 [9-19] months. Patients with events had higher native T1 (ms, 1149 [1115-1163] ms vs. 1110 [1075-1138] ms), native T2 (ms, 40 [38-41] vs. 37 [36-39]), LV mass index (g/m², 65 [49-77] vs. 57 [49-64]) p < 0.05 for all). In multivariable analyses, native T1 was independently predictive of adverse events (ChiSq 15.9, p < 0.001, native T1 (10 ms) hazard ratio (95% confidence interval) 1.20 (1.08-1.33), p = 0.001), followed by a model that also included LV mass (ChiSq 17.1, p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events.
Conclusions
Native myocardial T1 and LV mass by CMR, as opposed to traditional cardiovascular risk scores, predict cardiovascular outcome in PLWH, together reflecting the pathological myocardial remodeling of myocardial fibrosis and inflammation that potentially explain higher rates of HF in PLWH as compared to the non-infected population. These findings may inform personalized approaches to screening and early intervention to reduce the burden of HF.
Collapse
Affiliation(s)
- C Arendt
- Goethe University Hospital, Frankfurt, Germany
| | - P De Leuw
- Infektiologikum, Frankfurt am Main, Germany
| | - A Haberl
- Goethe University Hospital, Frankfurt, Germany
| | - G Kann
- Infektiologikum, Frankfurt am Main, Germany
| | - T Wolf
- Goethe University Hospital, Frankfurt, Germany
| | - C Stephan
- Goethe University Hospital, Frankfurt, Germany
| | | | - L Arcari
- Sapienza University of Rome, Rome, Italy
| | - M Vasquez
- Enrique Baltodano Briceño Hospital, Liberia, Costa Rica
| | - M Albrecht
- Goethe University Hospital, Frankfurt, Germany
| | - F Escher
- Institute of Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany
| | - T Vogl
- Goethe University Hospital, Frankfurt, Germany
| | - A Zeiher
- Goethe University Hospital, Frankfurt, Germany
| | - E Nagel
- Goethe University Hospital, Frankfurt, Germany
| | - V Puntmann
- Goethe University Hospital, Frankfurt, Germany
| |
Collapse
|
30
|
Kann G, Wetzstein N, Bielke H, Schuettfort G, Haberl AE, Wolf T, Kuepper-Tetzel CP, Wieters I, Kessel J, de Leuw P, Bickel M, Khaykin P, Stephan C. Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiation. J Infect 2021; 83:347-353. [PMID: 34242683 DOI: 10.1016/j.jinf.2021.06.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 05/27/2021] [Accepted: 06/30/2021] [Indexed: 11/17/2022]
Abstract
BACKGROUND HIV-infected patients with Pneumocystis-pneumonia (PCP) may develop paradoxical immune reconstitution inflammatory syndrome (IRIS), when combination antiretroviral therapy (cART) is started early during the course of PCP-treatment (PCPT). The aim of this study was to identify risk factors and predictors for PCP-IRIS and to improve individualized patient care. METHODS An ICD-10 code hospital database query identified all Frankfurt HIV Cohort patients being diagnosed with PCP from January 2010 - June 2016. Patient charts were evaluated retrospectively for demographic, clinical and therapeutic (cART/PCPT) characteristics and incidence of paradoxical IRIS according to French's case definitions. RESULTS IRIS occurred in 12/97 patients that started cART while on PCPT (12.4%). They had a higher rate of re-hospitalization (41.7vs. 4.7%; odds ratio (OR) 14.46; p = 0.009), intensive care treatment (66.7vs. 30.6%; OR = 4.54; p = 0.018), and longer median hospitalization (48 days vs. 23; p < 0.001). A high HIV-RNA level (> 6Log10/ml) before cART initiation was associated with IRIS development (41.6vs. 15.0%; OR 4.05; p = 0.042). Serum immunoglobulin G-levels (IgG) [mg/dl] were lower (894.0 vs. 1446.5; p = 0.023). CONCLUSION Higher hospitalization rate and morbidity parameters underscore the clinical importance of PCP-related paradoxical IRIS. A baseline viral load of > 6Log10/ml and serum IgG may help to assess individual risks for PCP-IRIS.
Collapse
Affiliation(s)
- Gerrit Kann
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Nils Wetzstein
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Hannah Bielke
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Gundolf Schuettfort
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Annette E Haberl
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Claus P Kuepper-Tetzel
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | - Imke Wieters
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany
| | | | | | | | | | - Christoph Stephan
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany.
| |
Collapse
|
31
|
Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, Rabenau HF, Corman VM, Drosten C, Vehreschild MJGT, Goetsch U, Gottschalk R, Ciesek S. Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro. J Infect Dis 2021; 224:1109-1114. [PMID: 34223909 PMCID: PMC8344430 DOI: 10.1093/infdis/jiab355] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 07/02/2021] [Indexed: 12/14/2022] Open
Abstract
Whether monoclonal antibodies are able to neutralise SARS-CoV-2 variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralise authentic SARS-CoV-2 including variant B.1.1.7 (Alpha) but variants B.1.351 (Beta) and P.2 (Zeta) were resistant against bamlanivimab and partially to casirivimab.
Collapse
Affiliation(s)
- Marek Widera
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Alexander Wilhelm
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Sebastian Hoehl
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Christiane Pallas
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Niko Kohmer
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Germany.,University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Holger F Rabenau
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Victor M Corman
- Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Center for Infection Research, DZIF, Braunschweig, Germany
| | - Christian Drosten
- Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Center for Infection Research, DZIF, Braunschweig, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Germany.,University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Udo Goetsch
- Public Health Department of the City of Frankfurt am Main, Frankfurt am Main, Germany
| | - Rene Gottschalk
- Public Health Department of the City of Frankfurt am Main, Frankfurt am Main, Germany
| | - Sandra Ciesek
- Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.,German Center for Infection Research, DZIF, Braunschweig, Germany.,Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, Frankfurt am Main, Germany
| |
Collapse
|
32
|
Keitel V, Jensen B, Feldt T, Fischer JC, Bode JG, Matuschek C, Bölke E, Budach W, Plettenberg C, Scheckenbach K, Kindgen-Milles D, Timm J, Müller L, Kolbe H, Stöhr A, Calles C, Hippe A, Verde P, Spinner CD, Schneider J, Wolf T, Kern WV, Nattermann J, Zoufaly A, Ohmann C, Luedde T. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22:343. [PMID: 34001215 PMCID: PMC8127198 DOI: 10.1186/s13063-021-05181-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 03/10/2021] [Indexed: 11/30/2022] Open
Abstract
Objectives Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate administered within 72 h of diagnosis of SARS-CoV-2 infection in adult individuals with pre-existing risk factors at higher risk of getting seriously ill with COVID-19. Camostat mesylate acts as an inhibitor of the host cell serine protease TMPRSS2 and prevents the virus from entering the cell. CP represents another antiviral strategy in terms of passive immunization. The working hypothesis to be tested in the RES-Q-HR study is that the early use of CP or camostat mesylate reduces the likelihood of disease progression to (modified) WHO stages 4b-8 in SARS-CoV-2-positive adult patients at high risk of moderate or severe COVID-19 progression. Trial design This study is a 4-arm (parallel group), multicenter, randomized (2:2:1:1 ratio), partly double-blind, controlled trial to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 infection and high risk for progression to moderate/severe COVID-19. Superiority of the intervention arms will be tested. Participants The trial is conducted at 10–15 tertiary care centers in Germany. Individuals aged 18 years or above with ability to provide written informed consent with SARS-CoV-2 infection, confirmed by PCR within 3 days or less before enrolment and the presence of at least one SARS-CoV-2 symptom (such as fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration of not more than 3 days. Further inclusion criteria comprise: Presence of at least one of the following criteria indicating increased risk for severe COVID-19:
Age > 75 years Chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis BMI > 40 kg/m2 Age > 65 years with at least one other risk factor (BMI > 35 kg/m2, coronary artery disease (CAD), chronic kidney disease (CKD) with GFR < 60 ml/min but ≥ 30 ml/min, diabetes mellitus, active tumor disease) BMI > 35 kg/m2 with at least one other risk factor (CAD, CKD with GFR < 60 ml/min but ≥ 30 ml/min, diabetes mellitus, active tumor disease)
Exclusion criteria:
Age < 18 years Unable to give informed consent Pregnant women or breastfeeding mothers Previous transfusion reaction or other contraindication to a plasma transfusion Known hypersensitivity to camostat mesylate and/or severe pancreatitis Volume stress due to CP administration would be intolerable Known IgA deficiency Life expectancy < 6 months Duration SARS-CoV-2 typical symptoms > 3 days SARS-CoV-2 PCR detection older than 3 days SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria) Previously or currently hospitalized due to SARS-CoV-2 Previous antiviral therapy for SARS-CoV-2 ALT or AST > 5 x ULN at screening Liver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial) Chronic kidney disease with GFR < 30 ml/min Concurrent or planned anticancer treatment during trial period Accommodation in an institution due to legal orders (§40(4) AMG). Any psycho-social condition hampering compliance with the study protocol. Evidence of current drug or alcohol abuse Use of other investigational treatment within 5 half-lives of enrolment is prohibited Previous use of convalescent plasma for COVID-19 Concomitant proven influenza A infection Patients with organ or bone marrow transplant in the three months prior to screening visit
Intervention and comparator Participants will be randomized to the following 4 groups:
Convalescent plasma (CP), 2 units at screening/baseline visit (day 0) or day 1; CP is defined by the presence of neutralizing anti-SARS-CoV-2 antibodies with titers ≥ 1:160; individuals with body weight ≥ 150 kg will receive a third unit of plasma on day 3 Camostat mesylate (200 mg per capsule, one capsule taken each in the morning, afternoon and evening on days 1–7) Standard of care (SOC, control for CP) Placebo (identical in appearance to camostat mesylate capsules, one capsule taken each morning, afternoon and evening on days 1–7; for camostat mesylate control group)
Participants will be monitored after screening/baseline on day 3, day 5, day 8, and day 14. On day 28 and day 56, telephone visits and on day 90, another outpatient visit are scheduled. Adverse events and serious adverse events will be monitored and reported until the end of the study. An independent data safety monitoring committee will review trial progression and safety. Main outcomes The primary endpoint of the study is the cumulative number of individuals who progress to or beyond category 4b on the modified WHO COVID-19 ordinal scale (defined as hospitalization with COVID-19 pneumonia and additional oxygen demand via nasal cannula or mask) within 28 days after randomization. Randomization Participants will be randomized using the Alea-Tool (aleaclinical.com) in a 2:2:1:1 ratio to the treatment arms (1) CP, (2) camostat mesylate, (3) standard of care (SoC), and (4) placebo matching camostat mesylate. Randomization will be stratified by study center. Blinding (masking) The camostat mesylate treatment arm and the respective placebo will be blinded for participants, caregivers, and those assessing outcomes. The treatment arms convalescent plasma and standard of care will not be blinded and thus are open-labeled, unblinded. Numbers to be randomized (sample size) Overall, n = 994 participants will be randomized to the following groups: n = 331 to convalescent plasma (CP), n = 331 to camostat mesylate, n = 166 to standard of care (SoC), and n = 166 to placebo matching camostat mesylate. Trial status The RES-Q-HR protocol (V04F) was approved on the 18 December 2020 by the local ethics committee and by the regulatory institutions PEI/BfARM on the 2 December 2020. The trial was opened for recruitment on 26 December 2020; the first patient was enrolled on 7 January 2021 and randomized on 8 January 2021. Recruitment shall be completed by June 2021. The current protocol version RES-Q HR V05F is from 4 January 2021, which was approved on the 18 January 2021. Trial registration EudraCT Number 2020-004695-18. Registered on September 29, 2020. ClinicalTrial.gov NCT04681430. Registered on December 23, 2020, prior to the start of the enrollment (which was opened on December 26, 2020). Full protocol The full protocol (V05F) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). Supplementary Information The online version contains supplementary material available at 10.1186/s13063-021-05181-0.
Collapse
Affiliation(s)
- Verena Keitel
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany.
| | - Björn Jensen
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Torsten Feldt
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Johannes C Fischer
- Institute for Transplant Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Johannes G Bode
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Christiane Matuschek
- Department of Radiation Oncology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Edwin Bölke
- Department of Radiation Oncology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Wilfried Budach
- Department of Radiation Oncology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Christian Plettenberg
- Department of Ear, Nose and Throat disease, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Kathrin Scheckenbach
- Department of Ear, Nose and Throat disease, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Detlef Kindgen-Milles
- Department of Anesthesiology, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | - Jörg Timm
- Institute for Virology, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Universitaetsstr. 1, D-40225, Duesseldorf, Germany
| | - Lisa Müller
- Institute for Virology, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Universitaetsstr. 1, D-40225, Duesseldorf, Germany
| | - Henrike Kolbe
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Andreas Stöhr
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Christian Calles
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Andreas Hippe
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Pablo Verde
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Christoph D Spinner
- Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Ismaninger Str. 22, D-81675, Munich, Germany
| | - Jochen Schneider
- Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Ismaninger Str. 22, D-81675, Munich, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany
| | - Winfried V Kern
- Department of Internal Medicine II, Infectious Diseases, University Hospital Freiburg, Hugstetter Str. 55, D-79106, Freiburg, Germany
| | - Jacob Nattermann
- Department of Internal Medicine I, University Hospital Bonn, Sigmund-Freud-Str. 25, D-53127, Bonn, Germany
| | - Alexander Zoufaly
- Department of Medicine IV, Kaiser Franz Josef Hospital, Kundratstrasse 3, 1100, Vienna, Austria
| | - Christian Ohmann
- Coordination Center for Clinical Studies, Medical Faculty, Heinrich Heine University Duesseldorf, D-40225 Duesseldorf, Germany
| | - Tom Luedde
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty Heinrich-Heine-University Duesseldorf, Moorenstr. 5, D-40225, Duesseldorf, Germany
| | | |
Collapse
|
33
|
Hentrich M, Müller M, Wyen C, Bogner J, Thomssen H, Wasmuth JC, Wolf T, Hoffmann C, Schommers P. Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol 2021; 194:642-646. [PMID: 33959944 DOI: 10.1111/bjh.17515] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 03/30/2021] [Accepted: 04/06/2021] [Indexed: 02/06/2023]
Affiliation(s)
- Marcus Hentrich
- Department of Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich, Germany
| | - Markus Müller
- Department of Infectiology, St. Joseph Hospital, Berlin, Germany
| | - Christoph Wyen
- Praxis Am Ebertplatz, Cologne, Germany.,Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Johannes Bogner
- Department of Medicine IV, Ludwig-Maximilians University of Munich, Munich, Germany
| | - Henrike Thomssen
- Department of Hematology and Oncology, Hospital Bremen Mitte, Bremen, Germany
| | | | - Timo Wolf
- Department of Medicine III, University Hospital Frankfurt, Frankfurt, Germany
| | - Christian Hoffmann
- ICH Study Center Hamburg, Hamburg, Germany.,Department of Medicine II, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Philipp Schommers
- Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.,Partner Site Bonn-Cologne, German Center for Infection Research (DZIF), Cologne, Germany
| |
Collapse
|
34
|
de Leuw P, Arendt CT, Haberl AE, Froadinadl D, Kann G, Wolf T, Stephan C, Schuettfort G, Vasquez M, Arcari L, Zhou H, Zainal H, Gawor M, Vidalakis E, Kolentinis M, Albrecht MH, Escher F, Vogl TJ, Zeiher AM, Nagel E, Puntmann VO. Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV. JACC Cardiovasc Imaging 2021; 14:1548-1557. [PMID: 33865770 DOI: 10.1016/j.jcmg.2021.01.042] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 12/30/2020] [Accepted: 01/28/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The goal of this study was to examine prognostic relationships between cardiac imaging measures and cardiovascular outcome in people living with human immunodeficiency virus (HIV) (PLWH) on highly active antiretroviral therapy (HAART). BACKGROUND PLWH have a higher prevalence of cardiovascular disease and heart failure (HF) compared with the noninfected population. The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood. METHODS This prospective observational longitudinal study included consecutive PLWH on long-term HAART undergoing cardiac magnetic resonance (CMR) examination for assessment of myocardial volumes and function, T1 and T2 mapping, perfusion, and scar. Time-to-event analysis was performed from the index CMR examination to the first single event per patient. The primary endpoint was an adjudicated adverse cardiovascular event (cardiovascular mortality, nonfatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization). RESULTS A total of 156 participants (62% male; age [median, interquartile range]: 50 years [42 to 57 years]) were included. During a median follow-up of 13 months (9 to 19 months), 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 nonfatal acute myocardial infarction, 1 appropriate device discharge, and 16 HF hospitalizations). Patients with events had higher native T1 (median [interquartile range]: 1,149 ms [1,115 to 1,163 ms] vs. 1,110 ms [1,075 to 1,138 ms]); native T2 (40 ms [38 to 41 ms] vs. 37 ms [36 to 39 ms]); left ventricular (LV) mass index (65 g/m2 [49 to 77 g/m2] vs. 57 g/m2 [49 to 64 g/m2]), and N-terminal pro-B-type natriuretic peptide (109 pg/l [25 to 337 pg/l] vs. 48 pg/l [23 to 82 pg/l]) (all p < 0.05). In multivariable analyses, native T1 was independently predictive of adverse events (chi-square test, 15.9; p < 0.001; native T1 [10 ms] hazard ratio [95% confidence interval]: 1.20 [1.08 to 1.33]; p = 0.001), followed by a model that also included LV mass (chi-square test, 17.1; p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events. CONCLUSIONS Our findings reveal important prognostic associations of diffuse myocardial fibrosis and LV remodeling in PLWH. These results may support development of personalized approaches to screening and early intervention to reduce the burden of HF in PLWH (International T1 Multicenter Outcome Study; NCT03749343).
Collapse
Affiliation(s)
- Philipp de Leuw
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany; Infektiologikum, Frankfurt am Main, Germany
| | - Christophe T Arendt
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Annette E Haberl
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Daniel Froadinadl
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Gerrit Kann
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Christoph Stephan
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Gundolf Schuettfort
- HIV Center, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Moises Vasquez
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Cardiology Department, Enrique Baltodano Briceño Hospital, Liberia, Costa Rica
| | - Luca Arcari
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
| | - Hui Zhou
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Radiology, XiangYa Hospital, Central South University, Changsha, Hunan, China
| | - Hafisyatul Zainal
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, Universiti Teknologi MARA (UiTM), Sg. Buloh, Malaysia
| | - Monika Gawor
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Warsaw, Warsaw, Poland
| | - Eleftherios Vidalakis
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Michael Kolentinis
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Moritz H Albrecht
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | - Thomas J Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Andreas M Zeiher
- Department of Cardiology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Eike Nagel
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Valentina O Puntmann
- Institute of Experimental and Translational Cardiac Imaging, DZHK (German Centre for Cardiovascular Research) Centre for Cardiovascular Imaging, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Cardiology, University Hospital Warsaw, Warsaw, Poland.
| |
Collapse
|
35
|
Matschinski A, Ziegler P, Abstreiter T, Wolf T, Drechsler K. Fiber Formation of Printed Carbon Fiber/Poly (Ether Ether Ketone) with Different Nozzle Shapes. POLYM INT 2021. [DOI: 10.1002/pi.6196] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A Matschinski
- Chair of Carbon Composites, TUM Department of Aerospace and Geodesy Technical University of Munich Garching Germany
| | - P Ziegler
- Chair of Carbon Composites, TUM Department of Aerospace and Geodesy Technical University of Munich Garching Germany
| | - T Abstreiter
- Chair of Astronautics, TUM Department of Aerospace and Geodesy Technical University of Munich Garching Germany
| | - T Wolf
- Chair of Carbon Composites, TUM Department of Aerospace and Geodesy Technical University of Munich Garching Germany
| | - K Drechsler
- Chair of Carbon Composites, TUM Department of Aerospace and Geodesy Technical University of Munich Garching Germany
| |
Collapse
|
36
|
Aprile E, Aalbers J, Agostini F, Ahmed Maouloud S, Alfonsi M, Althueser L, Amaro FD, Andaloro S, Antochi VC, Angelino E, Angevaare JR, Arneodo F, Baudis L, Bauermeister B, Bellagamba L, Benabderrahmane ML, Brown A, Brown E, Bruenner S, Bruno G, Budnik R, Capelli C, Cardoso JMR, Cichon D, Cimmino B, Clark M, Coderre D, Colijn AP, Conrad J, Cuenca J, Cussonneau JP, Decowski MP, Depoian A, Di Gangi P, Di Giovanni A, Di Stefano R, Diglio S, Elykov A, Ferella AD, Fulgione W, Gaemers P, Gaior R, Galloway M, Gao F, Grandi L, Hils C, Hiraide K, Hoetzsch L, Howlett J, Iacovacci M, Itow Y, Joerg F, Kato N, Kazama S, Kobayashi M, Koltman G, Kopec A, Landsman H, Lang RF, Levinson L, Liang S, Lindemann S, Lindner M, Lombardi F, Long J, Lopes JAM, Ma Y, Macolino C, Mahlstedt J, Mancuso A, Manenti L, Manfredini A, Marignetti F, Marrodán Undagoitia T, Martens K, Masbou J, Masson D, Mastroianni S, Messina M, Miuchi K, Mizukoshi K, Molinario A, Morå K, Moriyama S, Mosbacher Y, Murra M, Naganoma J, Ni K, Oberlack U, Odgers K, Palacio J, Pelssers B, Peres R, Pierre M, Pienaar J, Pizzella V, Plante G, Qi J, Qin J, Ramírez García D, Reichard S, Rocchetti A, Rupp N, Dos Santos JMF, Sartorelli G, Schreiner J, Schulte D, Schulze Eißing H, Schumann M, Scotto Lavina L, Selvi M, Semeria F, Shagin P, Shockley E, Silva M, Simgen H, Takeda A, Therreau C, Thers D, Toschi F, Trinchero G, Tunnell C, Valerius K, Vargas M, Volta G, Wei Y, Weinheimer C, Weiss M, Wenz D, Wittweg C, Wolf T, Xu Z, Yamashita M, Ye J, Zavattini G, Zhang Y, Zhu T, Zopounidis JP. Search for Coherent Elastic Scattering of Solar ^{8}B Neutrinos in the XENON1T Dark Matter Experiment. Phys Rev Lett 2021; 126:091301. [PMID: 33750173 DOI: 10.1103/physrevlett.126.091301] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 01/17/2021] [Accepted: 01/27/2021] [Indexed: 06/12/2023]
Abstract
We report on a search for nuclear recoil signals from solar ^{8}B neutrinos elastically scattering off xenon nuclei in XENON1T data, lowering the energy threshold from 2.6 to 1.6 keV. We develop a variety of novel techniques to limit the resulting increase in backgrounds near the threshold. No significant ^{8}B neutrinolike excess is found in an exposure of 0.6 t×y. For the first time, we use the nondetection of solar neutrinos to constrain the light yield from 1-2 keV nuclear recoils in liquid xenon, as well as nonstandard neutrino-quark interactions. Finally, we improve upon world-leading constraints on dark matter-nucleus interactions for dark matter masses between 3 and 11 GeV c^{-2} by as much as an order of magnitude.
Collapse
Affiliation(s)
- E Aprile
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Aalbers
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - F Agostini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - S Ahmed Maouloud
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Alfonsi
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - L Althueser
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - F D Amaro
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - S Andaloro
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - V C Antochi
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - E Angelino
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - J R Angevaare
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - F Arneodo
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - L Baudis
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - B Bauermeister
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - L Bellagamba
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | | | - A Brown
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - E Brown
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - S Bruenner
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - G Bruno
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R Budnik
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - C Capelli
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - J M R Cardoso
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - D Cichon
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - B Cimmino
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Clark
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - D Coderre
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A P Colijn
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - J Conrad
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - J Cuenca
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - J P Cussonneau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - M P Decowski
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - A Depoian
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - P Di Gangi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - A Di Giovanni
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - R Di Stefano
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - S Diglio
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - A Elykov
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A D Ferella
- Department of Physics and Chemistry, University of L'Aquila, 67100 L'Aquila, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - W Fulgione
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - P Gaemers
- Nikhef and the University of Amsterdam, Science Park, 1098XG Amsterdam, Netherlands
| | - R Gaior
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Galloway
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Gao
- Physics Department, Columbia University, New York, New York 10027, USA
- Department of Physics & Center for High Energy Physics, Tsinghua University, Beijing 100084, China
| | - L Grandi
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C Hils
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Hiraide
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - L Hoetzsch
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J Howlett
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Iacovacci
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - Y Itow
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - F Joerg
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - N Kato
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - S Kazama
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - M Kobayashi
- Physics Department, Columbia University, New York, New York 10027, USA
| | - G Koltman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - A Kopec
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - H Landsman
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - R F Lang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - L Levinson
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - S Liang
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - S Lindemann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - F Lombardi
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - J Long
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - J A M Lopes
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - Y Ma
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Macolino
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J Mahlstedt
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - A Mancuso
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - L Manenti
- New York University Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - A Manfredini
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - F Marignetti
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | | | - K Martens
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - J Masbou
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Masson
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Mastroianni
- Department of Physics "Ettore Pancini", University of Napoli and INFN-Napoli, 80126 Napoli, Italy
| | - M Messina
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Miuchi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - K Mizukoshi
- Department of Physics, Kobe University, Kobe, Hyogo 657-8501, Japan
| | - A Molinario
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Morå
- Physics Department, Columbia University, New York, New York 10027, USA
| | - S Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - Y Mosbacher
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - M Murra
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - J Naganoma
- INFN-Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, 67100 L'Aquila, Italy
| | - K Ni
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - U Oberlack
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - K Odgers
- Department of Physics, Applied Physics and Astronomy, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - J Palacio
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - B Pelssers
- Oskar Klein Centre, Department of Physics, Stockholm University, AlbaNova, Stockholm SE-10691, Sweden
| | - R Peres
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - M Pierre
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - J Pienaar
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - V Pizzella
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - G Plante
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J Qi
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - J Qin
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - D Ramírez García
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - S Reichard
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - A Rocchetti
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - N Rupp
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - J M F Dos Santos
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - G Sartorelli
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - J Schreiner
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - D Schulte
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - H Schulze Eißing
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Schumann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - L Scotto Lavina
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| | - M Selvi
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - F Semeria
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - P Shagin
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - E Shockley
- Department of Physics & Kavli Institute for Cosmological Physics, University of Chicago, Chicago, Illinois 60637, USA
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - M Silva
- LIBPhys, Department of Physics, University of Coimbra, 3004-516 Coimbra, Portugal
| | - H Simgen
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - A Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, and Kavli Institute for the Physics and Mathematics of the Universe (WPI), the University of Tokyo, Higashi-Mozumi, Kamioka, Hida, Gifu 506-1205, Japan
| | - C Therreau
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - D Thers
- SUBATECH, IMT Atlantique, CNRS/IN2P3, Université de Nantes, Nantes 44307, France
| | - F Toschi
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - G Trinchero
- INAF-Astrophysical Observatory of Torino, Department of Physics, University of Torino and INFN-Torino, 10125 Torino, Italy
| | - C Tunnell
- Department of Physics and Astronomy, Rice University, Houston, Texas 77005, USA
| | - K Valerius
- Institute for Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - M Vargas
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - G Volta
- Physik-Institut, University of Zürich, 8057 Zürich, Switzerland
| | - Y Wei
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - C Weinheimer
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - M Weiss
- Department of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - D Wenz
- Institut für Physik & Exzellenzcluster PRISMA, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - C Wittweg
- Institut für Kernphysik, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany
| | - T Wolf
- Max-Planck-Institut für Kernphysik, 69117 Heidelberg, Germany
| | - Z Xu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - M Yamashita
- Kobayashi-Maskawa Institute for the Origin of Particles and the Universe, and Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - J Ye
- Physics Department, Columbia University, New York, New York 10027, USA
- Department of Physics, University of California San Diego, La Jolla, California 92093, USA
| | - G Zavattini
- Department of Physics and Astronomy, University of Bologna and INFN-Bologna, 40126 Bologna, Italy
| | - Y Zhang
- Physics Department, Columbia University, New York, New York 10027, USA
| | - T Zhu
- Physics Department, Columbia University, New York, New York 10027, USA
| | - J P Zopounidis
- LPNHE, Sorbonne Université, Université de Paris, CNRS/IN2P3, Paris, France
| |
Collapse
|
37
|
Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle BS. Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021; 223:56-61. [PMID: 33128369 PMCID: PMC7665662 DOI: 10.1093/infdis/jiaa680] [Citation(s) in RCA: 54] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 10/26/2020] [Indexed: 12/18/2022] Open
Abstract
Background The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and hundreds of thousands of deaths. The infection causes COVID-19, a disease of the respiratory system of divergent severity. Here, the humoral immune response of a cohort of 143 COVID-19 patients from the University Hospital Frankfurt/Main, Germany was characterized. Methods SARS-CoV-2-specific antibodies were detected by enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 and hCoV NL63 neutralization activity was analyzed with pseudotyped lentiviral vectors. Results COVID-19 severity increased with age and male patients encountered more serious symptoms than females. Disease severity correlated with the amount of SARS-CoV-2 specific IgG and IgA and the neutralization activity of the antibodies. The amount of SARS-CoV-2 specific IgG antibodies decreased with time after PCR conformation of the infection and antibodies directed against the nucleoprotein waned faster than spike directed antibodies. In contrast, for the common flu coronavirus NL63, COVID19 disease severity seemed to correlate with low NL63-neutralizing activities, suggesting the possibility of cross-reactive protection. Conclusion The results describe the humoral immune responses against SARS-CoV-2 and might aid the identification of correlates of protection needed for vaccine development.
Collapse
Affiliation(s)
- Lisa Henss
- Paul-Ehrlich-Institut, Department of Virology, Langen, Germany
| | - Tatjana Scholz
- Paul-Ehrlich-Institut, Department of Virology, Langen, Germany
| | | | - Imke Wieters
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Frauke Borgans
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Fabian J Eberhardt
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Kai Zacharowski
- Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
| | - Sandra Ciesek
- Institut für Medizinische Virologie, Universitätsklinikum Frankfurt am Main, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Gernot Rohde
- Medizinische Klinik 1, Pneumologie/Allergologie, Universitätsklinikum Frankfurt-Goethe-Universität, Frankfurt am Main, Germany
| | - Maria Vehreschild
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Christoph Stephan
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Frankfurt am Main, Germany
| | - Heike Hofmann-Winkler
- Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Göttingen, Germany
| | | | | |
Collapse
|
38
|
Droste J, Kulisch M, Wolf T, Schaffert L, Schneiker-Bekel S, Pühler A, Kalinowski J. A maltose-regulated large genomic region is activated by the transcriptional regulator MalT in Actinoplanes sp. SE50/110. Appl Microbiol Biotechnol 2020; 104:9283-9294. [PMID: 32989516 PMCID: PMC7567727 DOI: 10.1007/s00253-020-10923-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 09/15/2020] [Accepted: 09/21/2020] [Indexed: 11/25/2022]
Abstract
Actinoplanes sp. SE50/110 is the industrially relevant producer of acarbose, which is used in the treatment of diabetes mellitus. Recent studies elucidated the expression dynamics in Actinoplanes sp. SE50/110 during growth. From these data, we obtained a large genomic region (ACSP50_3900 to ACSP50_3950) containing 51 genes, of which 39 are transcribed in the same manner. These co-regulated genes were found to be stronger transcribed on maltose compared with glucose as a carbon source. The transcriptional regulator MalT was identified as an activator of this maltose-regulated large genomic region (MRLGR). Since most of the genes are poorly annotated, the function of this region is farther unclear. However, comprehensive BLAST analyses indicate similarities to enzymes involved in amino acid metabolism. We determined a conserved binding motif of MalT overlapping the -35 promoter region of 17 transcription start sites inside the MRLGR. The corresponding sequence motif 5'-TCATCC-5nt-GGATGA-3' displays high similarities to reported MalT binding sites in Escherichia coli and Klebsiella pneumoniae, in which MalT is the activator of mal genes. A malT deletion and an overexpression mutant were constructed. Differential transcriptome analyses revealed an activating effect of MalT on 40 of the 51 genes. Surprisingly, no gene of the maltose metabolism is affected. In contrast to many other bacteria, MalT is not the activator of mal genes in Actinoplanes sp. SE50/110. Finally, the MRLGR was found partly in other closely related bacteria of the family Micromonosporaceae. Even the conserved MalT binding site was found upstream of several genes inside of the corresponding regions. KEY POINTS : • MalT is the maltose-dependent activator of a large genomic region in ACSP50_WT. • The consensus binding motif is similar to MalT binding sites in other bacteria. • MalT is not the regulator of genes involved in maltose metabolism in ACSP50_WT.
Collapse
Affiliation(s)
- Julian Droste
- Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Martin Kulisch
- Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Timo Wolf
- Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Lena Schaffert
- Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Susanne Schneiker-Bekel
- Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Alfred Pühler
- Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany
| | - Jörn Kalinowski
- Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615, Bielefeld, Germany.
| |
Collapse
|
39
|
Schuettfort G, Boekenkamp L, Cabello A, Cotter AG, De Leuw P, Doctor J, Górgolas M, Hamzah L, Herrmann E, Kann G, Khaykin P, Mallon PW, Mena A, Del Palacio Tamarit M, Sabin CA, Stephan C, Wolf T, Haberl AE. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors. HIV Med 2020; 22:47-53. [PMID: 33047484 DOI: 10.1111/hiv.12962] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 07/08/2020] [Accepted: 08/26/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The aim of the study was to investigate the efficacy and safety of first-line antiretroviral therapy (ART) with integrase inhibitor (INI) or protease inhibitor (PI)-based regimens in patients with low CD4 cell counts and/or an AIDS-defining disease. METHODS We conducted a retrospective, multicentre analysis to investigate discontinuation proportions and virological response in patients with CD4 cell counts < 200 cells/µL and/or AIDS-defining disease when starting first-line ART. Proportions of those discontinuing ART were compared using univariate analysis. Virological response was analysed using the Food & Drug Administration (FDA) snapshot analysis (HIV-1 RNA < 50 HIV-1 RNA copies/mL at week 48). RESULTS Two hundred and eighteen late presenters were included in the study: 13.8% were women and 23.8% were of non-European ethnicity, and the mean baseline CD4 count was 91 cells/µL (standard deviation 112 cells/µL). A total of 131 late presenters started on INI- and 87 on PI-based treatment. It was found that 86.1% of patients treated with INIs and 81.1% of patients treated with PIs had a viral load < 50 copies/mL at week 48; proportions of discontinuation because of adverse events were 6.1% in the INI group and 11.5% in the PI group. No significant differences in discontinuation proportions were observed at week 12 or 48 between INI- and PI-based regimens (P = 0.76 and 0.52, respectively). Virological response was equally good in those receiving INIs and those receiving PIs (86.1% vs. 81.1%, respectively; P = 0.36). CONCLUSIONS In a European cohort of late presenters starting first-line INI or PI-based ART regimens, there were no significant differences in discontinuation proportions or virological response at week 48.
Collapse
Affiliation(s)
- G Schuettfort
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - L Boekenkamp
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - A Cabello
- Infectious Diseases Outpatient Clinic, Hospital Fundación Jiménez Díaz, University Autónoma of Madrid, Madrid, Spain
| | - A G Cotter
- Department of Infectious Diseases, HIV Molecular Research Group, University College Dublin (UCD) School of Medicine, Mater Misericordae University Hospital, Dublin, Ireland
| | - P De Leuw
- Infektiologikum Frankfurt, Frankfurt, Germany
| | - J Doctor
- Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Górgolas
- Infectious Diseases Outpatient Clinic, Hospital Fundación Jiménez Díaz, University Autónoma of Madrid, Madrid, Spain
| | - L Hamzah
- St George's Hospital NHS Foundation Trust, London, UK
| | - E Herrmann
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - G Kann
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - P Khaykin
- MainFacharzt Frankfurt, Frankfurt, Germany
| | - P W Mallon
- Department of Infectious Diseases, HIV Molecular Research Group, University College Dublin (UCD) School of Medicine, Mater Misericordae University Hospital, Dublin, Ireland
| | - A Mena
- Department of Infectious Diseases, A Coruña University Hospital, A Coruña, Spain
| | - M Del Palacio Tamarit
- Infectious Diseases Outpatient Clinic, Hospital Fundación Jiménez Díaz, University Autónoma of Madrid, Madrid, Spain
| | - C A Sabin
- University College London, London, UK
| | - C Stephan
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - T Wolf
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - A E Haberl
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
40
|
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 2020; 182:1663-1673. [PMID: 32946786 DOI: 10.1101/2020.06.12.146290] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
SUMMARYThe SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and world economy. Since approved drugs and vaccines are not available, new options for COVID-19 treatment and prevention are highly demanded. To identify SARS-CoV-2 neutralizing antibodies, we analysed the antibody response of 12 COVID-19 patients from 8 to 69 days post diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days post diagnosis. Among these, 28 potently neutralized authentic SARS-CoV-2 (IC100as low as 0.04 μg/ml), showing a broad spectrum of V genes and low levels of somatic mutations. Interestingly, potential precursors were identified in naïve B cell repertoires from 48 healthy individuals that were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2 neutralizing antibodies are readily generated from a diverse pool of precursors, fostering the hope of rapid induction of a protective immune response upon vaccination.
Collapse
|
41
|
Wieters I, Eisermann P, Borgans F, Giesbrecht K, Goetsch U, Just-Nübling G, Kessel J, Lieberknecht S, Muntau B, Tappe D, Schork J, Wolf T. Two cases of airport-associated falciparum malaria in Frankfurt am Main, Germany, October 2019. ACTA ACUST UNITED AC 2020; 24. [PMID: 31822328 PMCID: PMC6905295 DOI: 10.2807/1560-7917.es.2019.24.49.1900691] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Two cases of presumably airport-acquired falciparum malaria were diagnosed in Frankfurt in October 2019. They were associated with occupation at the airport, and Plasmodium falciparum parasites from their blood showed genetically identical microsatellite and allele patterns. Both had severe malaria. It took more than a week before the diagnosis was made. If symptoms are indicative and there is a plausible exposure, malaria should be considered even if patients have not travelled to an endemic area.
Collapse
Affiliation(s)
- Imke Wieters
- These authors contributed equally to this work and share first authorship.,Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Philip Eisermann
- National Reference Centre for Tropical Pathogens, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,These authors contributed equally to this work and share first authorship
| | - Frauke Borgans
- Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Katharina Giesbrecht
- Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Udo Goetsch
- Municipal Health Protection Authority, Frankfurt am Main, Germany
| | - Gudrun Just-Nübling
- Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Johanna Kessel
- Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Simone Lieberknecht
- Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Birgit Muntau
- National Reference Centre for Tropical Pathogens, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Dennis Tappe
- National Reference Centre for Tropical Pathogens, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Joscha Schork
- These authors contributed equally to this work and share last authorship.,Municipal Health Protection Authority, Frankfurt am Main, Germany
| | - Timo Wolf
- These authors contributed equally to this work and share last authorship.,Infectious Diseases, Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
42
|
Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer N, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell 2020; 182:843-854.e12. [PMID: 32673567 PMCID: PMC7355337 DOI: 10.1016/j.cell.2020.06.044] [Citation(s) in RCA: 222] [Impact Index Per Article: 55.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 06/19/2020] [Accepted: 06/26/2020] [Indexed: 12/21/2022]
Abstract
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC100 as low as 0.04 μg/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.
Collapse
Affiliation(s)
- Christoph Kreer
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Matthias Zehner
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Timm Weber
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Meryem S Ercanoglu
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Lutz Gieselmann
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Cornelius Rohde
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany
| | - Sandro Halwe
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany
| | - Michael Korenkov
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Philipp Schommers
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
| | - Kanika Vanshylla
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Veronica Di Cristanziano
- Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany
| | - Hanna Janicki
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Reinhild Brinker
- Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany
| | - Artem Ashurov
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
| | - Verena Krähling
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany
| | - Alexandra Kupke
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany
| | - Hadas Cohen-Dvashi
- Department of Structural Biology, Weizmann Institute of Science, 76100 Rehovot, Israel
| | - Manuel Koch
- Institute for Dental Research and Oral Musculoskeletal Biology and Center for Biochemistry, University of Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany
| | - Jan Mathis Eckert
- Faculty of Medicine, University of Würzburg, 97080 Würzburg, Germany
| | - Simone Lederer
- Institute for Translational Bioinformatics, University Hospital Tübingen and University of Tübingen, 72076 Tübingen, Germany
| | - Nico Pfeifer
- Faculty of Medicine, University of Tübingen, 72076 Tübingen, Germany; Methods in Medical Informatics, Department of Computer Science, University of Tübingen, 72076 Tübingen, Germany; German Center for Infection Research, Partner Site Tübingen, 72076 Tübingen, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany
| | - Clemens Wendtner
- Department of Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilians University, 80804 Munich, Germany
| | - Ron Diskin
- Department of Structural Biology, Weizmann Institute of Science, 76100 Rehovot, Israel
| | - Henning Gruell
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany
| | - Stephan Becker
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany
| | - Florian Klein
- Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
| |
Collapse
|
43
|
Schüttfort G, Philipp K, de Leuw P, Herrmann E, Kann G, Khaykin P, Stephan C, Wolf T, Haberl A. Sex and Gender Differences in Rilpivirine based ART - Data from the HIVCENTER Frankfurt. Curr HIV Res 2020; 17:368-374. [PMID: 31686639 DOI: 10.2174/1570162x17666191104112557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 10/22/2019] [Accepted: 10/29/2019] [Indexed: 11/22/2022]
Abstract
OBJECTIVE While Rilpivirine has shown high overall response rates in treatment-naïve patients without sex and gender specific differences in clinical trials, Sex and gender specific data in treatment experienced patients receiving rilpivirine are still limited. We conducted a 48 week efficacy and safety analysis in naïve and treatment experienced men and women using retrospective data from the HIVCENTER Frankfurt. MATERIALS AND METHODS In this retrospective observational study data of all patients who received a rilpivirine based regimen at the HIVCENTER between March 2011 and December 2015 were analyzed. Primary endpoint was the proportion of patients with any discontinuation until week 48. Virologic response rates (FDA snapshot analysis; HIV-1 RNA <50 copies/mL) were assessed at week 48. RESULTS 194 patients (34% female) were included in the analysis. 74% were treatment-experienced and 26% naïve, respectively. Discontinuations were observed in 31 (15.9%) patients. Regarding sex differences, the proportion of discontinuations was significantly higher in women than in men (24.2% vs. 11.7%; p=0.024; ODDS-Ratio = 2.41; CI 1.12 - 5.18). Virologic failure occurred in 8 PLWHIV (4.1%). CONCLUSION While virologic overall response rates to rilpivirine based ART were high for both treatment-experienced and -naïve patients the proportion of discontinuations was significantly higher in women (24.2% vs. 11.7%; p = 0.024; ODDS-Ratio = 2.41; CI 1.12 - 5.18). Although the total number of patients with virologic failure was low (4.1%), the higher rate of ART discontinuations in female patients receiving RPV require close monitoring in the first months of treatment addressing special needs of women living with HIV.
Collapse
Affiliation(s)
- G Schüttfort
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - K Philipp
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - P de Leuw
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - E Herrmann
- Department of Biostatistics and Mathematical Modelling, Frankfurt, Germany
| | - G Kann
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | | | - C Stephan
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - T Wolf
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| | - A Haberl
- HIVCENTER, Department of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
44
|
Wolf T, Ellwanger R, Goetsch U, Wetzstein N, Gottschalk R. Fifty years of imported Lassa fever: a systematic review of primary and secondary cases. J Travel Med 2020; 27:5808990. [PMID: 32219400 DOI: 10.1093/jtm/taaa035] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 03/08/2020] [Indexed: 01/15/2023]
Abstract
RATIONALE FOR SYSTEMATIC REVIEW Lassa fever is the most common cause of imported haemorrhagic fevers cases in non-endemic countries. As a disease with a high case fatality rate that has regularly caused clusters of nosocomial transmission in endemic areas, prompt diagnosis is vital. We conducted a systematic review of imported cases of the last 50 years with the aim of defining the clinical and epidemiological characteristics that will enhance early diagnosis, prompt initiation of treatment and an appropriate public health response to Lassa fever cases. METHODS We performed a retrospective, systematic review of 36 primary and two secondary cases of Lassa fever in non-endemic countries outside West Africa by searching the PubMed database. This yielded 56 relevant publications that were included in our analysis. RESULTS The case fatality rate of 35.1% for imported cases was higher than that reported for endemic countries. The majority of patients showed clinical features consistent with Lassa fever and had a typical exposure. There was a considerable delay in diagnosis in imported cases with high associated numbers of contacts. Ribavirin was rarely used for post-exposure prophylaxis. Only two secondary transmissions occurred. Thirty-one percent of patients received Lassa fever-specific treatment and five required intensive care. CONCLUSIONS Although importation of Lassa fever to non-endemic countries is a rare event, it has repeatedly happened over five decades. Suspicion of Lassa fever should be based on careful consideration of clinical features and exposure history in order to assist early diagnosis in returning travellers from West Africa.
Collapse
Affiliation(s)
- Timo Wolf
- Department of Internal Medicine II-Infectious Diseases, University Hospital Frankfurtxs, Frankfurt, Germany
| | - Regina Ellwanger
- Department of Internal Medicine II-Infectious Diseases, University Hospital Frankfurtxs, Frankfurt, Germany.,Health Protection Authority, Municipality of Frankfurt am Main, Frankfurt, Germany
| | - Udo Goetsch
- Health Protection Authority, Municipality of Frankfurt am Main, Frankfurt, Germany
| | - Nils Wetzstein
- Department of Internal Medicine II-Infectious Diseases, University Hospital Frankfurtxs, Frankfurt, Germany
| | - Rene Gottschalk
- Health Protection Authority, Municipality of Frankfurt am Main, Frankfurt, Germany.,Institute of Medical Virology, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
45
|
Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord 2020; 42:102180. [PMID: 32408155 PMCID: PMC7202802 DOI: 10.1016/j.msard.2020.102180] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 04/25/2020] [Accepted: 05/02/2020] [Indexed: 01/18/2023]
Abstract
BACKGROUND Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients.
Collapse
Affiliation(s)
- Christian Foerch
- Department of Neurology, University Hospital, Goethe University, Schleusenweg 2-16, Frankfurt am Main 60528, Germany.
| | - Lucie Friedauer
- Department of Neurology, University Hospital, Goethe University, Schleusenweg 2-16, Frankfurt am Main 60528, Germany
| | - Boris Bauer
- Radiologie Sachsenhausen GmbH, Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, University Hospital, Goethe University, Frankfurt am Main, Germany
| | - Elisabeth H Adam
- Department of Anesthesiology, Intensive Care and Pain Therapy, University Hospital, Goethe University, Frankfurt am Main, Germany
| |
Collapse
|
46
|
Heidepriem J, Krähling V, Dahlke C, Wolf T, Klein F, Addo MM, Becker S, Loeffler FF. Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. Biotechnol J 2020; 15:e2000069. [PMID: 32463974 DOI: 10.1002/biot.202000069] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 04/29/2020] [Indexed: 12/26/2022]
Abstract
The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti-EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Here, the analysis of serum samples from an EBOV vaccine trial with the recombinant vesicular stomatitis virus-Zaire ebolavirus (rVSV-ZEBOV) and an Ebola virus disease survivor, using high-density peptide arrays, is presented. In this proof-of-principle study, distinct IgG and IgM antibodies binding to different epitopes of EBOV GP is detected: By mapping the whole GP as overlapping peptide fragments, new epitopes and confirmed epitopes from the literature are found. Furthermore, the highly selective binding epitope of a neutralizing monoclonal anti-EBOV GP antibody could be validated. This shows that peptide arrays can be a valuable tool to study the humoral immune response to vaccines in patients and to support Ebola vaccine development.
Collapse
Affiliation(s)
- Jasmin Heidepriem
- Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems, Potsdam, 14476, Germany
| | - Verena Krähling
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, Marburg, 35043, Germany.,German Center for Infection Research, partner site Gießen-Marburg-Langen, Marburg, 35043, Germany
| | - Christine Dahlke
- Division of Infectious Diseases, First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.,Department of Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, 20359, Germany.,German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, 20359, Germany
| | - Timo Wolf
- Department of Medicine, Infectious Diseases Unit, Goethe University Hospital, Frankfurt, 60590, Germany
| | - Florian Klein
- Laboratory of Experimental Immunology, Institute of Virology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, 50931, Germany.,Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine, Cologne, 50931, Germany.,German Center for Infection Research, partner site Bonn-Cologne, Cologne, 50931, Germany
| | - Marylyn M Addo
- Division of Infectious Diseases, First Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.,Department of Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, 20359, Germany.,German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, 20359, Germany
| | - Stephan Becker
- Institute of Virology, Faculty of Medicine, Philipps University Marburg, Marburg, 35043, Germany.,German Center for Infection Research, partner site Gießen-Marburg-Langen, Marburg, 35043, Germany
| | - Felix F Loeffler
- Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems, Potsdam, 14476, Germany
| |
Collapse
|
47
|
Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild MJGT, Kann G, Wolf T, Gottschalk R, Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 2020; 382:1278-1280. [PMID: 32069388 PMCID: PMC7121749 DOI: 10.1056/nejmc2001899] [Citation(s) in RCA: 415] [Impact Index Per Article: 103.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
| | - Holger Rabenau
- University Hospital Frankfurt, Frankfurt am Main, Germany
| | | | | | | | - Denisa Bojkova
- University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Pia Behrens
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Boris Böddinghaus
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Udo Götsch
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Frank Naujoks
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Peter Neumann
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Joscha Schork
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Petra Tiarks-Jungk
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Antoni Walczok
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | | | | | - Gerrit Kann
- University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Timo Wolf
- University Hospital Frankfurt, Frankfurt am Main, Germany
| | - René Gottschalk
- Health Protection Authority, City of Frankfurt, Frankfurt am Main, Germany
| | - Sandra Ciesek
- University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
48
|
Wetzstein N, Kohl TA, Andres S, Schultze TG, Geil A, Kim E, Biciusca T, Hügel C, Hogardt M, Lehn A, Vehreschild MJGT, Wolf T, Niemann S, Maurer FP, Wichelhaus TA. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex. Int J Infect Dis 2020; 93:320-328. [PMID: 32147539 DOI: 10.1016/j.ijid.2020.02.059] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 02/27/2020] [Accepted: 02/27/2020] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE Phenotypic (Sensititre Myco, pDST) and genotypic drug susceptibility testing (GenoType NTM DR, gDST) in M. avium complex (MAC) have become available as standardized assays, but comparable data is needed. This study aimed to investigate the phenotypic and genotypic drug susceptibility patterns in MAC clinical isolates. METHODS Overall, 98 isolates from 85 patients were included. pDST and gDST were performed on all isolates and results compared regarding specificity and sensitivity using pDST as a reference method. The impact of drug instability on pDST results was studied using a biological assay over 14 days. In addition, the evolution of antimicrobial resistance was investigated in sequential isolates of 13 patients. RESULTS Macrolide resistance was rare, 1.2% (95% CI 0.7-7.3) of isolates in the base cohort. No aminoglycoside resistances were found, but 14.1% of the studied isolates (95% CI 7.8-23.8) showed intermediate susceptibility. The GenoType NTM DR identified two out of four macrolide-resistant isolates. Antibiotic stability was demonstrated to be poor in rifampicin, rifabutin, and doxycycylin. CONCLUSIONS pDST results in NTM for unstable antibiotics must be interpreted with care. A combination of pDST and gDST will be useful for the guidance of antimicrobial therapy in MAC-disease.
Collapse
Affiliation(s)
- Nils Wetzstein
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
| | - Thomas A Kohl
- German Center for Infection Research, Research Center Borstel, Borstel, Germany; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany; National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany
| | - Sönke Andres
- National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany
| | - Tilman G Schultze
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Ari Geil
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Eunhee Kim
- Department of Radiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Teodora Biciusca
- Department of Radiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Christian Hügel
- Department of Pneumology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Michael Hogardt
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; German National Consiliary Laboratory on Cystic Fibrosis Bacteriology, Germany
| | - Annette Lehn
- Institute of Biostatistics and Mathematical Modeling, Goethe University, Frankfurt am Main, Germany
| | - Maria J G T Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Timo Wolf
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Stefan Niemann
- German Center for Infection Research, Research Center Borstel, Borstel, Germany; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany; National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany
| | - Florian P Maurer
- National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany; Institute of Medical Microbiology, Virology and Hospital Hygiene, University Medical Center Hamburg- Eppendorf, Hamburg, Germany
| | - Thomas A Wichelhaus
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| |
Collapse
|
49
|
Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z. New filovirus disease classification and nomenclature. Nat Rev Microbiol 2020; 17:261-263. [PMID: 30926957 DOI: 10.1038/s41579-019-0187-4] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Jens H Kuhn
- Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
| | - Takuya Adachi
- Department of Infectious Diseases, Toshima Hospital, Tokyo, Japan
| | - Neill K J Adhikari
- Critical Care Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Canada
| | - Jose R Arribas
- Internal Medicine Department, Infectious Diseases Unit Madrid, Hospital La Paz-Carlos III IdiPAZ, Madrid, Spain
| | | | | | | | - Matthias Borchert
- Centre for International Health Protection, Robert Koch Institute, Berlin, Germany
| | - Arne Broch Brantsæter
- Division of Medicine, Department of Infectious Diseases and Norwegian National Unit for CBRNE Medicine, University of Oslo, Oslo, Norway
| | - David M Brett-Major
- Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD, USA
| | - Timothy H Burgess
- Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD, USA
| | - Daniel S Chertow
- Critical Care Medicine Department, Emerging Pathogens Section, National Institutes of Health Clinical Center, Bethesda, MD, USA
| | - Christopher G Chute
- Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, MD, USA
| | - Theodore J Cieslak
- Department of Epidemiology, University of Nebraska Medical Center, College of Public Health, Omaha, NE, USA
| | | | - Ian Crozier
- Integrated Research Facility at Fort Detrick, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research supported by the National Cancer Institute, Frederick, MD, USA
| | - Richard T Davey
- Clinical Research Section, Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | | | - Rafael Delgado
- Molecular Microbiology, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
| | - Laura Evans
- Division of Pulmonary and Critical Care Medicine, NYU Langone Medical Center, New York, NY, USA
| | | | - William A Fischer
- Department of Medicine, Division of Pulmonary Disease and Critical Care Medicine, Chapel Hill, NC, USA
| | - Tom E Fletcher
- Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool Institute of Translational Medicine and National Institute for Health Research, Liverpool, United Kingdom
| | - Robert A Fowler
- Departments of Medicine and Critical Care Medicine, Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Center, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | | | - Andy Hall
- King's Sierra Leone Partnership, King's Centre for Global Health, King's College London & King's Health Partners, London, UK
| | | | - Andy I M Hoepelman
- Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, Netherlands
| | | | - Giuseppe Ippolito
- Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" (National Institute for Infectious diseases "Lazzaro Spallanzani" - IRCCS), Rome, Italy
| | - Shevin T Jacob
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Michael Jacobs
- Department of Infection, Royal Free London NHS Foundation Trust, London, UK
| | | | - Frederique A Jacquerioz
- Division of Tropical and Humanitarian Medicine, University Hospitals of Geneva, Geneva, Switzerland
| | - Laurent Kaiser
- Geneva Center for Emerging Viral Diseases, Geneva, Switzerland
| | - Andre C Kalil
- University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Jimmy Kapetshi
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
| | - Hans-Dieter Klenk
- Institute of Virology, Philipps University of Marburg, Marburg an der Lahn, Hesse, Germany
| | - Gary Kobinger
- Department of Microbiology, Immunology and Infectious Diseases, Université Laval, Québec City, Québec, Canada
| | - Mark G Kortepeter
- Department of Epidemiology, University of Nebraska Medical Center, College of Public Health, Omaha, NE, USA
| | | | - Thomas Kratz
- Federal Information Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Henry S Kyobe Bosa
- College of Health Sciences, School of Public Health, Makerere University, Kampala, Uganda
| | - Marta Lado
- Partners in Health (PIH), Freetown, Sierra Leone
| | | | - H Cliff Lane
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Leslie Lobel
- Shraga Segal Department of Microbiology, Immunology and Genetics, School of Pharmacy, Center for Emerging Diseases, Tropical Diseases and AIDS, Ben Gurion University of the Negev, Beer-Sheva, Israel
| | - Julius Lutwama
- Uganda Virus Research Institute, Arbovirology Emerging and Re-emerging Diseases, Entebbe, Uganda
| | | | - Moses B F Massaquoi
- Sub-Regional Consortium on Ebola Vaccine and Therapeutic Trials, Clinton Health Access Initiative - Liberia, Boston, MA, USA
| | | | | | | | - Srinivas Murthy
- Faculty of Medicine, University of British Columbia, Vancouver, Canada
| | | | - Jean-Jacques Muyembe-Tamfum
- Department of Microbiology, University of Kinshasa Medical School, Kinshasa, Democratic Republic of the Congo
| | - Phiona Nakyeyune
- London School of Hygiene & Tropical Medicine, London, United Kingdom
| | | | - Miriam Nanyunja
- Department of Communicable Diseases, World Health Organization, Kampala, Kampala District, Uganda
| | - Justus Nsio-Mbeta
- Direction Générale de Lutte contre la Maladie, Kinshasa, Democratic Republic of the Congo
| | - Tim O'Dempsey
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Janusz T Pawęska
- Center for Emerging, Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, 2131, Sandringham-Johannesburg, Gauteng, South Africa
| | | | - Peter Piot
- London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - Christophe Rapp
- Department of Infectious and Tropical Diseases, Bégin Military Teaching Hospital, Saint-Mande, France
| | - Bertrand Renaud
- Faculté de Médecine, Université de Paris Descartes, Paris, France
| | - Bruce Ribner
- Emory University School of Medicine, Atlanta, GA, USA
| | - Pardis C Sabeti
- Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA
| | | | - Werner Slenczka
- Institute of Virology, Philipps University of Marburg, Marburg an der Lahn, Hesse, Germany
| | - Moses J Soka
- Partnership for Ebola Virus Disease Research in Liberia, Monrovia Medical Units ELWA-2 Hospital, Monrovia, Liberia
| | | | - James Strong
- Public Health Agency of Canada, Special Pathogens Program, Ottawa, Ontario, Canada
| | - Robert Swanepoel
- Vectors and Vector-Borne Diseases Research Programme, Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa
| | - Timothy M Uyeki
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | | | - Pauline Vetter
- Geneva Center for Emerging Viral Diseases, Geneva, Switzerland
| | - David A Wohl
- Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Timo Wolf
- University Hospital, Frankfurt am Main, Germany
| | - Anja Wolz
- Médecins Sans Frontières, Brussels, Belgium
| | - Alie H Wurie
- Sierra Leone Ministry of Health and Sanitation, Freetown, Sierra Leone
| | - Zabulon Yoti
- World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of the Congo
| |
Collapse
|
50
|
Stecher M, Wasmuth JC, Knops E, Eis-Hübinger A, Bogner J, Spinner C, Eberle J, Lehmann C, Degen O, Rockstroh J, Altfeld M, Wolf T, Mueller MC, Scholten S, Wyen C, Jessen H, Postel N, Pauli R, Wolf E, Eger J, Schäfer G, Stellbrink HJ, Krsnaric I, Heger E, Kastenbauer U, Behrens G, Fätkenheuer G, Vehreschild J. 1269. Cohort Profile: The Translational Platform HIV (TP-HIV), a Multicenter Cohort Project in Germany. Open Forum Infect Dis 2019. [PMCID: PMC6809352 DOI: 10.1093/ofid/ofz360.1132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Background While Germany has a long tradition in HIV research with many well-established regional cohorts, there was a lack of collaborative efforts toward harmonized data collection and biobanking, both key strategies for efficient translational research projects. Key challenges are heterogeneity of data systems and privacy concepts, of existing study and data collection protocols, and sample collection, storage, and sharing. Methods In 2013, we established the Translational Platform HIV (TP-HIV) with support of the German Centre for Infection Research (DZIF) as a collaboration between university hospitals and specialized HIV care centers throughout Germany. After assessing the individual needs of all partner sites, we have taken comprehensive action to create a common platform for collaboration in all research stages. We developed protocols, rules of operation, biobanking strategies, and privacy concepts for all collaborating partner sites. Patients infected with HIV (PLWH) who sign the informed consent for the TP-HIV are pro- and retrospectively included in the cohort. Results To date, the TP-HIV infrastructure is implemented at 27 member sites from 11 cities, potentially extending to more than 20,000 patients currently treated for HIV across Germany. Facing the special needs in the German research environment, the TP-HIV established a unique data- and biomaterial collection allowing expedited translational research and reduce project overheads, regulatory burden, and data security regulations for investigators. By active surveillance, rapid access to individual patient groups such as patients with acute HIV infection, TP-HIV is an ideal platform for early phase clinical trials with new drug candidates. Researchers with clinical, biological, epidemiological, and statistical expertise have been brought together within the TP-HIV, which enables an effective translational chain from bench to bedside and back. New collaborations have been established with currently 23 active study protocols. Conclusion The TP-HIV has demonstrated to be a powerful tool for generating and testing research hypotheses in PLWH. In the future, we will work to further expand our network and address the pressing needs in the German research environment. Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Melanie Stecher
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Nordrhein-Westfalen, Germany
| | - Jan-Christian Wasmuth
- Department for Internal Medicine I, University Hospital of Bonn, Bonn, Nordrhein-Westfalen, Germany
| | - Elena Knops
- Institute of Virology, University Hospital of Cologne, Colohne, Nordrhein-Westfalen, Germany
| | - Anna Eis-Hübinger
- Institute of Virology, University of Bonn Medical Center, Bonn, Nordrhein-Westfalen, Germany
| | - Johannes Bogner
- Internal Medicine IV – University Hospital Munich, Ludwig-Maximilians-University, Munich, Bayern, Germany
| | - Christoph Spinner
- Department of Medicine II, University Hospital Rechts der ISAR, Technical University of Munich, Munich, Bayern, Germany
| | - Josef Eberle
- Max von Pettenkofer Institute and Gene Center, Munich, Berlin, Germany
| | - Clara Lehmann
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Nordrhein-Westfalen, Germany
| | - Olaf Degen
- University Hospital Hamburg Eppendorf, Hamburg, Germany
| | - Jürgen Rockstroh
- Department for Internal Medicine I, University Hospital of Bonn, Bonn, Nordrhein-Westfalen, Germany
| | | | - Timo Wolf
- HIV Center, University Hospital of Frankfurt, Frankfurt, Hessen, Germany
| | - Matthias C Mueller
- Division of Infectious Diseases, Department of Medicine II, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Baden-Wurttemberg, Germany
| | - Stefan Scholten
- Medical practice Hohenstaufenring, Köln, Nordrhein-Westfalen, Germany
| | - Christoph Wyen
- Medical practice Ebertplatz, Cologne, Nordrhein-Westfalen, Germany
| | | | - Nils Postel
- Medical Practice prinzmed,München, Bayern, Germany
| | - Ramona Pauli
- Medical Practice Isartor, Munich, Bayern, Germany
| | - Eva Wolf
- Muc Research GmbH, Munich, Bayern, Germany
| | - Johanna Eger
- Center for Internal Medicine and Infectious Diseases (ZIMI), Munich, Bayern, Germany
| | - Guido Schäfer
- University Hospital Hamburg Eppendorf, Hamburg, Germany
| | | | - Ivanka Krsnaric
- Center for Infectious Diseases Berlin (zibp), Berlin, Germany
| | - Eva Heger
- Institute of Virology, University Hospital of Cologne, Colohne, Nordrhein-Westfalen, Germany
| | | | - Georg Behrens
- Hannover Medical School, Hannover, Niedersachsen, Germany
| | - Gerd Fätkenheuer
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Nordrhein-Westfalen, Germany
| | - Jörg Vehreschild
- University Hospital of Cologne, Cologne, Nordrhein-Westfalen, Germany
| |
Collapse
|